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CHAPTER 1
GENERAL INTRODUCTION
&
SCOPE OF THIS THESIS
The General Introduction is based on the follwing articles
Immunotherapy for renal cell carcinoma.
Eur Urol. 2003 Jul;44(1):65-75.
Tumor antigens and markers in renal cell carcinoma.
Urol Clin North Am. 2003 Aug;30(3):455-65.
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1.1 Epidemiology & Etiology of RCC
Renal cell carcinoma (RCC) is the most common renal tumor, the third malignancy within uro-
logical oncology and comprises 2-3% of all malignancies. RCC was conventionally thought to
arise primarily from the proximal convoluted tubules. Indeed, this is the case for most of the
clear-cell subtype of RCC (ccRCC), which accounts for 70% to 80% of all RCCs . However,
other histological subtypes e.g. papillary or chromophobic RCC, typically arise from more
distal components of the nephron. RCC occurs twice as often in men compared to women and
the highest incidence of RCC is seen in the 6th decade [1,2]. The incidence of RCC is rising.
Review of over 10.000 cases of RCC gathered in the Connecticut Tumor Registry indicate a
six-fold increase in the incidence of RCC from 1935-1989; both in woman and men [3].
Several risk factors have been described for RCC. Tobacco smoking doubles the risk of RCC
and there is a positive linear relation between body weight and the risk for RCC, especially in
women. Other factors associated with higher risk for RCC are exposure to asbestos or chemi-
cals, thiazide drug intake and urinary tract infections [4].
In the onset of RCC there are only few early warning signs. The classical triad of Virchow,
consisting of an abdominal mass together with flank pain and macroscopic hematuria, is nowa-
days only seen in approximately 5% of the new cases presenting with RCC. If any, the presen-
tation of the disease is accompanied with non-specific signs as fatigue, weight loss, malaise,
fever and/or night sweats [5]. At present, more then 50% of all RCC are found incidentally.
The incidence of these so-called incidentalomas has risen from 15 to over 50% in the past
decades. Typically, these incidentalomas are of smaller size, often confined within the renal
capsule and associated with a favorable clinical outcome.
1.2 Prognostic factors and staging systems
In order to adequately assess the success rate of current and future treatment modalities, con-
tinuous evaluation of prognostic factors and staging systems is essential. Historically, several
staging systems have been used in parallel. The realization that one international staging
system for RCC is important has led to the general acceptance of the current tumor-node-meta-
stasis staging system (TNM) published in 2002 [6] (table 1).
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The TNM staging system addresses the anatomic extend of the tumor and recognizes 4 subdi-
visions. I: T1N0M0, II: T2N0M0, III: T3N0-1M0 and T1-2N1M0, IV: T4N0-2M0-1 and any
TN2M0 and anyTN0-1M1 [7] (table 2).
At present, tumor stage is still the most important prognostic factor for the clinical outcome of
RCC [8]. Nevertheless, the natural history of RCC is complicated and influenced by numerous
factors. Accurate prediction of clinical outcomes of patients with RCC immediately after
resection of localized disease would be beneficial for counseling, follow-up evaluation and
identification of high risk patients potentially suitable for adjuvant therapies and clinical trials.
It has become increasingly clear that the clinical behavior of RCC results from interactions
among multiple variables. As a result,
nomograms and integrated staging
systems have been developed to
improve the predictive capabilities of
physicians. Several of these systems,
in particular the UCLA integrated sta-
ging system, are discussed in chapter
2 of this thesis.
1.3 Tumor markers
A new development in cancer research is the identification of molecular tumor markers. Tumor
markers can be of great value in several aspects of cancer treatment. For prostate cancer (PCa)
the use of markers has become daily routine. 
Prostate specific antigen (PSA) has long since been used as a serum tumor marker to detect
15
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T1b Tumor greater than 4.0 cm, but no more than 7.0 cm, in greatest dimension, limited to the kidney. 
T2 Tumor greater than 7.0 cm in greatest dimension, limited to the kidney. 
T3 Tumor extends into major veins, or invades adrenal or perinephric tissues but not beyond Gerota’s fascia.
T3a Tumor invades adrenal gland or perinephric tissues but not beyond Gerota’s fascia. 
T3b Tumor grossly extends into renal vein(s) or vena cava below the diaphragm. 
T3c Tumor grossly extends into vena cava above the diaphragm. 
T4 Tumor invades beyond Gerota’s fascia. 
N0 No regional lymph node metastasis. 
N1 Metastasis to a single regional lymph node. 
N2 Metastasis in more than one regional lymph node. 
M0 No distant metastasis. 
M1 Distant metastasis. 
 
Table 1
TNM staging system 2002 [6]
Stage T N M 5-year survival  
I 1 0 0 91% 
II 2 0 0 74% 
III 
1 
2 
3 
1 
1 
0, 1 
0 
0 
0 
67% 
IV 
4 
Any 
Any 
0, 1 
2 
Any 
0 
0 
1 
32% 
Table 2
Subdivisions of the TNM staging system and 5-year survival [7]
relapse of PCa [9]. Moreover, PSA is used for population screening and diagnosis. Recently,
DD3PCA3 has been described as the most PCa-specific gene that is strongly over-expressed
in >95% of primary PCa specimens and in PCa metastasis [10,11]. Evaluation of a time-resol-
ved fluorescence-based quantitative RT-PCR assay for the detection of DD3PCA3 transcripts
in urinary sediments obtained after extensive prostatic massage showed a high negative pre-
dictive value for the presence of PCa [12]. The use of this PCa-specific marker may have a
great impact for the reduction of the number of prostate-biopsies currently needed to detect
PCa.
Also for RCC numerous studies have been published that describe the potential use of tumor-
associated biomarkers in the diagnosis and prognosis of RCC and as targets for (gene-immu-
no) therapy strategies. Tumor markers can be classified according to their origin and function.
· Apoptotic markers
· Proliferation markers
· Cell adhesion markers
· Tumor associated antigens
· Angiogenisis
· Cytogenetics
1.3.1. Apoptotic regulators & cell cycle proteins
As mentioned, RCC shows a high degree of resistance to chemotherapy and radiation [13,14].
The loss of control of apoptosis may contribute to progression and resistance to treatment
modalities and can be attributed to an interaction between p53 and the apoptotic regulators bcl-
2 and Bax [15]. However, the majority of RCC express normal function of the protein p53 and
analysis of expression of p53, bcl-2, or Bax could not be significantly correlated with other
parameters examined including tumor recurrence, metastasis, or survival rate [16].
Aberrations in the G1-S transition have been observed in a variety of tumors, suggesting that
cell cycle defects are related to the activation of oncogenes and inactivation of suppressor
genes involved in the transformation process. The frequency of G1/S aberrations in RCC has
not been fully clarified. Cyclins (A and D1), pRb, p21 (waf1/cip1) and p27 (KIP1) are cellu-
lar proteins involved in the tight regulation of cell cycle events. Several groups have studied
the relation between these markers and clinical and histopathological parameters as well as to
clinical outcome [17-21]. Review of these studies suggests that Cyclin-A, but mainly low 
expression p27 is associated with poor prognosis for patients with RCC.
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1.3.2. Proliferation Markers 
Proliferation of cells is unmistakably related to cancer and subsequently, several proliferation
markers have been evaluated. AgNOR (Silver stained nucleolar-organizing regions) reflects
transcription activity of ribosomal DNA and mitotic activity. PCNA (Proliferating cell nucle-
ar antigen) is a protein synthesized in the later G1 and S phases of the cell cycle. Finally, Ki-
67 (MIB1) is a monoclonal antibody that stains a proliferating-specific antigen in tumor cells.
All these markers have been correlated to histological grade and stage and even survival [22-
24]. Comparative studies that have been performed suggest that Ki-67 is the more powerful
prognostic factor of the three [25,26]; nevertheless more multivariate studies are needed.
1.3.3. Cell Adhesion Markers
Cancer metastasis is a complex multistage process. Decreased intercellular adhesion enables
detachment of tumor cells and can play a role in the early steps of the metastatic process. Cell
adhesion can be mediated through at least four families of adhesion molecules (intergrin,
immunoglobulin, selectin, and cadherin). Also the tubular epithelium, from which the RCC
originates, expresses a complex set of adhesion molecules. During carcinogenisis, the combi-
nation of cadherin expression changes in almost 50% of RCC [27]. E-cadherin, a Ca++-depen-
dent epithelial cadherin, is considered as a critical molecule for epithelial integrity [28].
However, most RCCs do not express E-cadherin because renal proximal tubular epithelium
from which RCCs originate does not express E-cadherin. In contrast, other studies showed that
in normal kidney tubular epithelium N-cadherin and cadherin-6 are expressed [29,30] and that
expression patterns may be related to the metastatic behavior of the tumor. The cadherin func-
tion is modulated through cytoplasmic proteins termed catenins. Immuno-histochemical stai-
ning revealed that catenins were expressed in all the segments of the nephron including proxi-
mal tubules. The catenin family seems to be less divergent than the cadherin family. Therefore,
it was reasoned that there might be a correlation between aggressiveness of RCC and a decre-
ased expression of alpha-catenin, which is a member of the catenins that link cadherin to the
cytoskeleton. Immuno-histochemical staining on RCC using antibodies against E-cadherin and
alpha-catenin has revealed that the ratios of abnormal staining for E-cadherin and alpha-cate-
nin were 77% and 37%, respectively. The prognostic value of E-cadherin is controversial.
However, a significant correlation between survival and decreased expression of alpha-catenin
was observed. Whether alpha-catenin immuno-histochemistry provides additional prognostic
information remains to be established.
Although cell adhesion molecules are usually membrane-bound, soluble forms (sICAM-1,
sVCAM-1 and sELAM-1) exist and are generated by shedding of the extracellular portions
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from the cell surface. These molecules have been investigated along with other clinical para-
meters in patients with metastatic RCC [31,32]. The prognostic significance of sICAM-1
might indicate a role of this molecule for tumor progression, potentially in association with the
abrogation of anti-tumor immune responses. The possibility of defining a pretreatment risk
model based on sICAM-1 level, ESR and CRP also warrants further investigation, with regard
to a possible linkage between acute phase proteins and sICAM-1 levels.
CD44 is a transmembrane glycoprotein involved in cell-cell and cell-matrix interactions. De
novo expression of CD44 and its variant isoforms have been associated with aggressive beha-
vior in various tumors [33,34]. Since few data are available concerning the role of CD44 in the
biological behavior of locally confined renal tumors, the expression of CD44 in a large set of
18
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Table 3
Overview of tumor markers in renal cell carcinoma
Renal Cell Carcinoma Tumor markers  Reference 
Apoptotic regulators 
 
 
 
 
Cell Cylcle proteins 
 
 
 
 
 
Proliferation markers 
 
 
 
 
Cell adhesion markers 
 
 
 
 
 
 
 
 
 
 
Tumor associated antigens 
 
 
 
Angiogenic markers 
 
 
 
Cytogeic markers 
 
 
p53 
bcl-2 
Bax 
 
 
cyclin A and D1 
p21 (waf1/cip-1) 
p27 (KIP1) 
pRb 
 
 
AgNOR 
PCNA 
Ki-67 (MIB1) 
 
 
E-cadherin 
N-Cadherin 
Cadherin-6 
α-catenin 
sICAM1 
sVCam-1 
sECam-1 
CD44 
 
 
 
RAGE 
CA-IXG250/MN 
 
 
Intratumoral microvascular density 
VEGF 
 
 
Karyometry 
Myc 
 
 
15,16,22 
 
 
 
 
17-21 
 
 
 
 
 
22-26 
 
 
 
 
27-30 
 
 
 
31,32 
 
33,34 
 
 
 
50 
52,57 
 
 
35,36 
37,38 
 
 
39-42 
44,46 
 
conventional RCC was analyzed to determine its prognostic value in association with other cli-
nico-pathologic variables [34]. The investigators concluded that CD44 expression was corre-
lated with progression and survival of RCC patients and can be considered as a useful prog-
nostic parameter in conventional renal cell carcinoma and may be used in evaluation of the
outcome of these tumors.
1.3.4. Angiogenic Markers
Neovascularization is inextricable related to tumor growth and metastatic dissemination.
Nevertheless, angiogenisis measured as intratumoral microvascular density is not an indepen-
dent prognostic factor in RCC [35,36].Vascular endothelial growth factor (VEGF) is definite-
ly related to histological grade and stage, the prognostic value remains uncertain [37]. Besides
its association with grade and stage, VEGF may also play a role in the treatment of RCC. A
recent publication described the effect of bevacizumab, a neutralizing antibody against vascu-
lar endothelial growth factor (VEGF), in the treatment of mRCC [38]. In this randomized, dou-
ble blind phase 2 trial, placebo was compared with 2 doses of bevacizumab. The primary end-
point of this study was the time to progression of disease. According to intention-to-treat ana-
lysis, progression-free survival in the group receiving the high dose bevacizumab (10mg/kg)
was significantly longer (median: 4.8 months) than in the placebo group (median: 2.5 months,
P<0.001 by the log-rank test). The NCI data safety and monitoring board recommended clo-
sure of accrual on the basis of these differences in time to progression, despite an overall res-
ponse rate of approximately 10%, and no difference in survival between the three study-arms.
1.3.5. Cytogenetic Markers
Recently it has become widely accepted that genetic alterations play an important role in the
development of many cancers. The relationship of abnormal nuclear morphology to molecular
genetic alterations in RCC is unknown. Nuclear morphometric analyses have been used suc-
cessfully to predict the outcome of patients with cancer when classical pathologic grading
systems failed. Indeed, several investigations showed a significant correlation between mor-
phometric parameters and survival of patients with RCC [39-42]. Nevertheless, in colorectal
carcinoma, it was shown that nuclear morphology seemed not to be directly influenced by the
individual genetic alterations but was by fractional allelic loss (i.e., a global measure of gene-
tic changes) [43]. Thus, it might be suggested that complex tumor properties such as patholo-
gic appearance and metastatic potential cannot be understood unless most of the underlying
genetic factors are taken into consideration. Therefore several chromosomal abnormalities and
subsequent over-expression of proteins have been evaluated. L-myc and C-myc, for instance,
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are a family of proto-oncogenes that have been studied in RCC [44]. yet, so far only associa-
tions could be made with histological grade and stage, without showing independent prog-
nostic significance [44-46].
1.3.6. Tumor-Associated Antigens: CA-IXG250/MN
Markers that are in particular of interest for in the optimalization of gene-immunotherapy are
RCC-associated antigens. However, despite compelling evidence that RCC is an immunoge-
nic tumor, until recently only a few specific tumor antigens, such as RAGE, are known.
RAGE, initially defined through CTL technology, is expressed in a minor percentage of RCC,
and therefore a sub optimal target [47-51]. In this aspect the identification of the RCC-associ-
ated antigen CA-IXG250/MN (CA9) is of interest. 
CA9 is expressed in >95% of all ccRCC tumors. Moreover, no expression can be detected in
normal kidney tissue, including fetal kidney, and in other normal tissues the expression is high-
ly restricted and limited to large bile ducts and gastric epithelium [52]. Furthermore, CA9 is
also expressed in several non-RCC tumors. In RCC, the chimeric monoclonal antibody G250
(WX-G250) which recognizes the CA9 antigen, has been identified and developed for both
therapeutical and diagnostical purposes [52]. Furthermore, a CA9-derived peptide recognized
by HLA-A2.1 restricted CTL and a helper peptide recognized by HLA-DR restricted T-helper
cells have been identified [53,54]. These findings, together with the high prevalence of CA9
in RCC make this antigen a promising tool for specific immunotherapy strategies for RCC
[55,56].
The high expression of CA9 in ccRCC implies the involvement of CA9 in renal carcinogeni-
sis. CA9 is a member of the carbonic anhydrase family, which are enzymes involved in acid-
base balance, CO2 transport and ion exchange, which explains their physiological expression
in the gastric mucosa. Still, the involvement of CA9 in the carcinogenis remains to be elucida-
ted. CA9 cDNA transfection into CA9 negative cell lines did not alter the cell doubling time
and did not lead to immortilazation (pers. communication). Thus, CA9 seems not to function
as an oncogene. It is known that the acidic environment around tumors favor their malignant
behavior, and this might explain the expression of CA9 in a variety of tumors. However, it is
also conceivable that CA9 is up regulated only to correct the carcinogenic acidic environment,
instead of creating it.
Using the clinical and data resources of the UCLA Kidney Cancer Program, Bui et al investi-
gated whether CA9 is associated with progression and survival [57]. Immunohistochemical
analysis using a CA9 mAb was performed on tissue microarrays from patients treated by neph-
rectomy for ccRCC. CA9 staining was correlated with response to treatment, clinical factors,
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pathological features, and survival. Low CA9 staining was an independent poor prognostic
factor for survival for patients with metastatic RCC, with a hazard ratio of 3.10 (P < 0.001).
CA9 significantly substratified patients with metastatic disease when analyzed by T stage,
Fuhrman grade, nodal involvement, and performance status (P < 0.001, P = 0.001, P = 0.009,
and P = 0.005, respectively). Overall expression of CA9 decreased with development of meta-
stasis, as demonstrated by the lower CA9 staining levels in metastatic lesions relative to mat-
ched primary tumor specimens (P = 0.036). On the basis of these data, CA9 seems to be the
most significant molecular marker described in kidney cancer, to date.
1.4 The von Hippel-Lindau Gene and RCC
Von Hippel-Lindau disease is a hereditary multisystem cancer syndrome caused by germline
mutations of the VHL tumor-suppressor gene on the short arm of chromosome 3 (reviewed in
[58]. The disease predisposes to the development of a variety of highly vascularized benign
and malignant tumors of the central nervous system, adrenal glands, pancreas reproductive
adnexal organs and the kidney. VHL-disease is the principal cause of inherited RCC.
Furthermore, in almost 100% of the sporadic ccRCC there is an inactivation of the VHL-gene
either by mutation, deletion or methylation [59,60].
VHL plays a central role in the cellular oxygen homeotasis. In normoxic conditions the VHL-
protein (pVHL) binds and deactivates the hypoxia-inducible factor-1a (HIF-1a). However, in
hypoxic condition pVHL does not target HIF-1a for degradation leading to an increased tran-
scription of a variety of HIF-regulated genes. Tumors, e.g. ccRCC, in which both alleles of the
VHL gene are inactive mimic the hypoxic situation; leading to an overproduction of HIF-1a
and subsequently the HIF-1a targeted genes (VEGF, GLUT1, TGF-a, CA9), several of which
have been discussed in this chapter [61,62]. Besides cacinogenisis through the HIF-1a path-
way, the VHL-status has also been associated with effects on apoptosis (Bcl-pathway) and cell
cycle events (p27, cyclin-D). Many of these HIF-targeted genes are associated with aggressi-
ve tumor growth, suggesting that gene products of the VHL/HIF-1a pathway are important
prognostic factors. Furthermore, the same VHL/HIF-1a pathway is of interest to develop mole-
cular therapeutic interventions (discussed in [63]).
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1.5 Summary of Tumor Markers
Tumor markers are mainly used to diagnose specific malignancies. The methods commonly
involve immuno-histochemistry and cytogenetics, including fluorescent in situ hybridisation
(FISH), and reversed transcriptase (RT) and polymerase chain reaction (PCR). In RCC seve-
ral investigated tumor markers are promising (summarized in table 3). They may show addi-
tional prognostic value over classical prognostic factors like stage and grade. Also, these mar-
kers can finally be used for a better patient selection, development of specific gene-immuno-
therapy strategies and a better follow-up. Ultimately these factors should show its value in a
prospective well-controlled manner and additionally, more research is needed to obtain new
(better) antigens and markers in RCC. Also, the association with the carcinogenisis of RCC
and the inactivation of the VHL-gene with subsequent over-expression of several tumor-asso-
ciated genes is intriguing and should be elucidated.
1.6. Therapeutic approaches in RCC
The treatment of RCC is dependent on the anatomic extend of the disease, as addressed by the
TNM staging system. Localized disease, that is, if no metastatic disease is observed, is treated
by means of surgical removal of the tumor. Nevertheless, up to 30% of all patients treated with
curative intent will develop distant metastasis, especially patients within TNM stage III or IV.
Review of 3502 patients with metastatic RCC (mRCC) treated with one of 72 chemotherapeu-
tic agents revealed a cumulative objective response rate of only 2 - 6 % [64]. This is the con-
sequence of intrinsic or acquired resistance of renal cancer cells to chemotherapeutic drugs, as
discussed earlier. Combination therapy and/or radiotherapy does not significantly change res-
ponse rates or survival [65]. Therefore, chemo- and radiotherapy are considered to be of limi-
ted value for the treatment of mRCC.
RCC is one of the few tumors where spontaneous regression of metastatic disease after tumor-
nephrectomy has been documented [66]. Therefore, much attention has been focused on
immunotherapeutical modalities for the treatment of mRCC. 
22
Chapter 1
1.7. The immune system
Already at the beginning of the twentieth century Paul Ehrlich suggested that cells are often
undergoing malignant transformation ('aberrant germs') and that this process was controlled by
the immune system. Later, Burnet and Thomas have further developed this concept as the
immune surveillance hypothesis, speculating that the immune system was constantly searching
for aberrant cells and consequently destroying them at pre-clinical stage. Furthermore, it was
proposed that immune surveillance played a role in growth delay of established tumors.
Recently, this concept has been refined and renamed immunoediting[67].
Current literature indicates that T-cells are probably the major factor for both cellular and
humoral immunological control of tumor growth (figure 1). To activate the cellular immune
pathway, class I and class II major histocompatibility complex (MHC) molecules bind to short
peptides of 8-10 and 13-20 amino acids, respectively. This peptide-MHC complex is recogni-
zed by the T-cell receptor on the surface of T lymphocytes leading to an immunological synap-
se; whether a tumor-associated antigen (TAA)-derived peptide elicits a cellular T-cell respon-
se is regulated by the quality of this synapse.
Humoral antitumor responses
are regulated by antibodies
that mediate their effect
mainly through antibody
dependent cellular cytotoxi-
city (ADCC). Tumor cell
lysis by ADCC is regulated
by the interaction between
the Fc-region of an antibody
bound to a tumor cell and the
Fcg receptors on immune
effector cells, such as neutro-
phils, macrophages and natu-
ral killer (NK) cells [68].
Interactions of NK cells with
IgG antibodies via the
FcgRIII receptor are well
known to induce a signal
transduction cascade leading
23
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Antibodies 
CTL 
Tumor cell with antigens 
Memory T-cell 
Second antigen exposure 
Plasma cell 
Antigen presenting cell 
Humoral response Cellular response 
B-cell T-cytotoxic 
Memory B-cell 
T-helper 
Fig. 1
Overview of the humoral and cellular pathway of the immune system.
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to ADCC as well as the release of various cytokines involved in anti-tumor responses [69]. The
different immunotherapeutical modalities currently used and investigated to elicit immune res-
ponses against RCC will be reviewed.
1.8. Non-specific immunotherapy
1.8.1. Interferon
Interferons (IFNs) are cytokines that are already present under normal physiological circum-
stances albeit at low levels. Their expression is greatly enhanced after exposure to different sti-
muli, e.g. viruses. Three different classes of IFNs have been described: IFN-alpha, IFN-beta
and IFN-gamma. The mechanisms of action of IFNs in clinical oncology have not been clari-
fied, but some are thought to be stimulation of phagocytosis by macrophages, upregulation of
MHC class I molecules and direct antitumor activities [70].
The clinical relevance of IFN-beta and IFN-gamma in the treatment of advanced RCC has not
been proven [65,71,72]. For IFN-alpha, two large randomized studies of interest have been
published. In the trial performed by the Medical Research Council Collaborators (MRC) [73],
IFN-alpha (10 MIU three times weekly) was compared with 300mg of the orally administered
hormonal drug medroxyprogesterone acetate (MPA). Treatment with IFN-alpha led to an
improved 1-year survival of 12% (MPA 31% survival, IFN-alpha 43%), and an improvement
in median survival of 2,5 months (MPA 6 months, IFN-alpha 8,5 months). A trial performed
by Pyrhonen et al showed that the combination of IFN-alpha and vinblastine (VLB) was supe-
rior to VLB alone[74]. Since VLB has not shown to enhance the effect of IFN-alpha [75,76],
the results of the latter trial must be due to the IFN-alpha treatment.
13-Cis-retinoic acid (CRA), a vitamin A derivative, can markedly upregulate the differentia-
tion and proliferation of normal and neoplastic cells and synergistic effects of IFN and CRA
have been described [77]. Motzer et al presented the results of a phase III trial comparing IFN-
alpha alone with IFN-alpha in combination with CRA [78]. Patients received either daily sub-
cutaneous (s.c.) injections of an escalation dose of IFN-alpha (3 MIU to 9 MIU), or this regi-
men combined with 1mg/kg CRA per day. Despite the higher response rate for the combina-
tion therapy (6% versus 12%) no difference was found in median survival time (15 months for
all patients). The trend that sustained remissions for IFN-sensitive tumors were observed when
combination therapy was given, needs to be confirmed with long-term follow-up data. A simi-
lar study (EORTC 30951) has been completed in January 2001 and the results will be mature
within the second half of 2003.
1.8.2. Interleukin-2
Interleukin (IL)-2 is mainly produced by CD4+ T-cells, but also by CD8+ T-cells and large gra-
nular lymphocytes. The actions of IL-2 comprise the stimulation of e.g. NK-cells to secrete
different cytokines like IFN-alpha, tumor necrosis factor (TNF-alpha) and granulocyte-macro-
phage colony-stimulating factor (GM-CSF), which activates the monocyte/macrophage linea-
ge [79]. Consequently, differentiation of lymphokine-activated killer (LAK) cells [80], matu-
ration of antigen presenting cells (APC) and enhanced ADCC [81] are induced. In 1995, Fyfe
et al published the results obtained in 255 patients with mRCC treated with high-dose intrave-
nous (IV) bolus regimens using doses of either 600.000 or 720.000 IU/kg. In this patient popu-
lation, 15% showed an objective response (CR: 7%; PR: 8%). These results led to the USA
Food and Drug Administration (FDA)-approved use of IL-2 in the treatment of mRCC [82].
Severe side effects like hypotension, pulmonary edema and renal dysfunction were 
observed during high-dose bolus IL-2 treatment with a treatment-related mortality of up to 4%.
With the intention to diminish the severe side effects [83], clinical trials evaluating continuous
high-dose intravenous infusion or subcutaneous (SC) administration of IL-2 were performed.
Collective data showed a clear decrease in toxicity with comparable response rates [84,85].
However, no randomized studies of sufficient size have been published today.
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Table 4
Overview of cytokine-based immunotherapy trials for renal cel carcinoma
Author 
[reference] # Pts Treatment Overall Response  in % Median Survival (months) 
Survival 
Benefit 
MRC & Collab. 
[73]  335 IFN versus MPA 
13 (IFN) 
7  (MPA) 
8.5 mo (IFN) 
6.0 mo (MPA) Yes 
Pyrhonen [74] 160 IFN + V versus V 16.5 (IFN + V) 2.5  (V) 
67.6 weeks (IFN + V) 
37.8 weeks (V) Yes 
Motzer [78] 284 IFN + CRA   
versus IFN 
12 (IFN + CRA) 
6  (IFN) 
15 mo (IFN + CRA) 
15 mo (IFN) No 
Fyfe [82] 255 IL-2  14 16.3 mo N/a 
Negrier [88] 425 IL-2 versus IFN 
versus IL-2 + IFN 
6.5  (IL-2) 
7.5  (IFN) 
18.6 (IL-2 + IFN) 
13 mo (IL-2), 
12 mo (IFN), 
17 mo (IL-2 + IFN) 
No 
Atzpodien [91] 78 IL-2 + IFN + 5-FU 
versus T 
39.1 (IL-2 + IFN + 5-FU) 
0 (T) 
24 mo (IL-2 + IFN + 5-FU) 
13 mo (T) Yes 
Van Herpen [92] 52 IL-2 + IFN + 5-FU 12 16.5 mo N/a 
Negrier [93] 131 IL-2 + IFN + 5-FU 
versus IL-2 + IFN 
8.2  (IL-2 + IFN + 5-FU) 
1.4  (IL-2 + IFN) 
12 mo (IL-2 + IFN + 5-FU) 
12 mo (IL-2 + IFN) No 
Abbreviations: #Pts: number of patients, MRC: Medical Research Counsil, IFN: interferon-alpha, MPA:
medroxyprogeterone acetate, mo: months, V: vinblastine, CRA: 13-cis-retinoic acid, IL-2: Interleukin-2, N/a:
not applicable (no control study arm), 5-FU: 5-fluorouracil, T: tamoxifen.
1.8.3. Combination therapy
Different combinations of cytokines, e.g. IL-2 with IFN-beta [86], IFN-gamma and GM-CSF
[87] have been studied in the treatment of mRCC. However, none as extensive as the combi-
nation of IL-2 and IFN-alpha. One of the most informative studies was conducted by the
Groupe Francais d'Immunotherapie [88]. This is the only clinical trial so far in which patients
were randomized between IL-2, IFN-alpha or the combination of the two cytokines. Patients
received either (a) rIL-2, which was administered as a five-day continuous IV infusion at a
dose of 18 MIU m-2 per day. The treatment schedule consisted of two induction cycles and
four maintenance cycles, with a three-week rest period between cycles. Each induction cycle
consisted of two five-day courses of IL-2 infusion separated by a six-day break. Each mainte-
nance cycle consisted of a five-day infusion followed by three weeks of no therapy (b) 18 MIU
of IFN-alpha 3 times a week for the 10 weeks SC, or (c) rIL-2 as described plus a reduced dose
of IFN-alpha of 6 MIU 3 times a week. Higher response rates for the combination therapy were
found (6.5%, 7.5% and 18.6% respectively) and at one year the event-free survival rates were
15, 12 and 20% respectively. Still, the overall survival did not differ significantly between the
study arms.
Although treatment of mRCC with chemotherapy has no impact on survival [1], pre-clinical
data have shown synergistic effects of 5-fluorouracil (5-FU), IFN-alpha, and IL-2 [89,90],
which led to the initiation of several clinical trials evaluating this combination therapy.
Atzpodien et al [91] performed a prospective randomized trial comparing the combination of
IL-2, IFN-alpha and 5-FU (triple therapy) with hormone therapy (tamoxifen 80mg twice daily
over 8 weeks) in 78 patients with mRCC. The treatment group showed an objective response
rate of 39.1% (95%CI, 24.2-55.5) against
no objective remissions in the group of
patients receiving tamoxifen. However,
several other trials have not been able to
confirm the high response percentages
of the triple therapy for mRCC (table 4)
[92-94]. Currently, a definitive
MRC/EORTC (30012) trial is ongoing
comparing this regimen with IFN-alpha
monotherapy.
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Bad Performance status WHO > 1 
Loss of weight >10% in last 6 months 
Short disease to treatment  
interval  < 2 years 
Localization of metastasis Metastasis in liver, bone or brains 
Number of metastatic lesions > 1 metastatic site 
Nephrectomy  No nephrectomy (possible) 
Laboratory parameters 
     Sedimentation rate 
     LDH 
     Neutrophiles 
     Hemoglobine 
 
>70 mmHg/h 
>280 U/l 
>6x109/l 
<6.3 mmol/l 
Table 5
Risk factors for a short survival in patients with mRCC [98]
1.8.4.Long-term efficacy of non-specific immunotherapy
In 2000, the long-term survival update of patients who received high-dose bolus IL-2 was
published [95]. Although the median survival for all patients was not altered (16.3 months),
the median response duration for all objective responders was 54 months, with a range of 3 to
>131 months. The median duration of the complete responders was not even reached (>80
months, range: 3 to 131+ months). Furthermore, 10% to 20% of the total number of included
patients were estimated to be alive 5 to 10 years following IL-2 treatment. Similar long-term
survival data have been observed with either IL-2 alone [96] or IL-2 in combination with IFN-
alpha both with and without CRA and/or 5-FU [97]. These data indicate that cytokine-based
therapy has the capacity to induce durable responses in a subset of patients. An important chal-
lenge is to select those
patients most likely to bene-
fit from cytokine-based the-
rapy, emphasizing the need
for large randomized trials
comparing different cytoki-
ne regimes for patients
within a variety of defined
risk groups. Endpoints of
these trials should be both
survival and quality of life.
1.8.5.Prognostic factors indicating the outcome of non-specific immunotherapy
As stated, it is important to define prognostic factors able to predict clinical response following
cytokine-based therapy [98]. Several factors related to short survival of mRCC are shown in
table 5 [82,88,99-101]. Based on the number of risk factors patients can be divided into prog-
nostic groups to compare clinical results of patients receiving immunotherapy. This has been
done for patients who received IL-2 [101,102] and IFN-alpha [103], and particularly patients
with a good performance status, only one metastatic lesion and an interval from diagnosis to
systemic therapy of more than 24 months showed a greater survival (table 6). 
The role of nephrectomy in the treatment of mRCC has long been debated. However, recent-
ly two trials clearly showed survival benefit for patients undergoing nephrectomy prior to cyto-
kine treatment [104,105]. Because this leads to a therapeutic advantage in only a minority of
patients undergoing immunotherapy, tumornephrectomy before treatment remains controver-
sial. Bex et al [106] evaluated immunotherapy with the primary tumor in place and tumorneph-
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Prognostic groups are defined as the sum of the number of points of three
prognostic factors [99,101,102]. These prognostic groups were: (a) PS=per-
formance status according to the World Health Organization: PS of 0 (fully
active; able to carry on all pre-disease activities without restriction) = 0
points and PS of 1 (restricted in physically strenuous activity but ambulato-
ry and able to carry otut work of light or sedentary nature) = 1 point; disea-
se to treatment interval: 0=>24 months and 1=<24 months; number of meta-
static sites: 0=one localization and 1= more than one localization.
Median survival (days) after treatment with Prognostic groups 
(total points) IL-2 INF-alpha Chemotherapy 
   Good (0 or 1) 570 652 352 
   Intermediate (2) 320 315 202 
   Poor (3) 177 193 158 
Table 6
Comparison of the survival of prognostic groups of patients with mRCC
treated with immunotherapy or chemotherapy [98]
rectomy was only performed when a clinical response or stabilization was observed. Although
this study was underpowered, a substantial number of patients were spared surgery.  In short,
the fact that immunotherapy in combination with the removal of the primary tumor reveals a
time to progression- and a survival benefit, has been well established. However, a randomized
trial is needed to evaluate the precise timing of cytoreductive therapy in combination with
immunotherapy with regard to morbidity, overall survival and quality of life.
1.9. Adoptive cellular therapy
1.9.1. Lymphokine activated killer cells & Tumor infiltrating lymphocytes.
An alternative method to induce immune responses against RCC is the transfer of immune
effector cells with antitumor reactivity. Two of these so-called "adoptive cellular therapy"
approaches are LAK and TIL [107]. LAK cells are lymphoid cells found in the population of
the large granular lymphocytes of the peripheral blood, which can be activated following in-
vitro stimulation with supraphysiological concentrations of IL-2 and can subsequently be rein-
fused in the patient. LAK cells mediate antitumor activity in a non-specific manner. TIL cells
are a population of lymphocytes infiltrating the tumor tissue that contain both non-specific
cells (e.g. NK-cells), but also tumor specific cytotoxic T cells (CTL). TIL cells can be isolated
from the tumor specimen, expanded ex-vivo in IL-2, and reinfused into the patient. The above-
mentioned therapies showed great potential in in-vitro settings and animal models and led to
an improved understanding of tumor-immunology. Nevertheless, randomized clinical trials
comparing these new treatment options with IL-2 and/or IFN-alpha showed no additional cli-
nical benefit [107]. 
1.9.2. Allogeneic stem cell transplantation
A new and effective form of adoptive cellular therapy against various forms of hematological
malignancies is allogeneic stem cell transplantation (allo-SCT). In the setting of allo-SCT, T-
cell reactivity against minor histocompatibility antigens is the suggested mechanism of action
[108]. This method has also been explored for mRCC. In two comparable studies safety, fea-
sibility and clinical results of allo-SCT after non-myeloablative chemotherapy were evaluated
[109,110]. Both trials show that a graft-versus-tumor effect can be induced with objective res-
ponse rates of 53% and 33% respectively. However, substantial toxicity due to graft-versus-
host disease (GVHD) occurred and a transplantation-related mortality of 33% and 12% was
observed in the two trials respectively. T cell depleted bone marrow may facilitate graft take
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while preventing GVHD and subsequent donor lymphocyte infusions (DLI) may give rise to
an anti-tumor effect which does not necessarily parallel GVHD [111]. These observations have
formed the basis of a clinical study ongoing at our institution that evaluates the progression-
free survival of partially T cell depleted allo-SCT followed by DLI in patients with poor risk
lymphoma, colorectal carcinoma and mRCC.
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Chapter 1
Outline of the thesis
Despite the fact that evaluation of cytokine-based therapies for mRCC shows that a subset of
patients react favorable to immunotherapy, significant side effects do occur. With the increa-
sed knowledge of tumor-immunology, the recognition of immunogenic tumor proteins and
antibodies, new treatment options with increased specificity and subsequently less side-effects
are of interest. In this thesis several studies have been performed to evaluate these new treat-
ment options.
Chapter 2 discusses the need for a staging sytem that adequately discriminates patients with
RCC into prognostic groups in order to provide improved counseling, follow-up evaluation
and identification of high risk patients potentially suitable for adjuvant therapies and clinical
trials. This chapter presents a clinical algorithm using 3 well-known prognostic factors that can
be used to predict survival and stratify patients undergoing nephrectomy for localized disease
into 3 risk groups. External data from 2 outside institutions suggest the validity of this algo-
rithm with a high concordance index. These risk categories can be used in clinical trial design
and interpretation as well as in clinical management areas such as surveillance.
Chapters 3 & 4 discuss dendritic cell-based immunotherapy. Dendritic cells (DC) are the most
potent antigen presenting cells (APC’s) of the immune system with the ability to stimulate
naive resting T cells to proliferate and differentiate into activated cytotoxic T cells specific
against the presented antigen. Two clinical trials were performed evaluating safety and clini-
cal or immunological responses of DC-based vaccines. 
Chapters 5 & 6 deal with monoclonal antibody-based immunotherapy. Currently, several
monoclonal antibodies (mAb) are used in cancer treatment. In RCC the chimeric mAb G250
(WX-G250) has been identified and developed for both therapeutical and diagnostical purpo-
ses. Antibody dependent cellular cytotoxicity (ADCC) has been suggested to be the main
effector mechanism of WX-G250 and in-vitro data  showed that interleukin-2 (IL-2) has the
capacity to up-regulate WX-G250 mediated ADCC. This led to the initiation of two successi-
ve clinical trials evaluating infusions of WX-G250 as monotherapy and the combination of
WX-G250 with a low-dose IL-2 pulsing regimen
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CHAPTER 2
VALIDATION OF AN INTEGRATED STAGING SYSTEM TOWARDS
IMPROVED PROGNOSTICATION OF PATIENTS WITH LOCALIZED
RENAL CELL CARCINOMA IN AN INTERNATIONAL POPULATION
Published: J Urol. 2003 Dec;170(6 Pt 1):2221-4. 
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2.1 Abstract
Purpose: Outcome prediction for patients with renal cell carcinoma is based on a combination
of factors.  In this study, a previously published clinical outcome algorithm based on 1997 T
stage, Fuhrman grade, and performance score is validated using an international database.
Methods: A total of 1060 patients from 3 databases (St Radboud = SR, MD Anderson= MDA,
and UCLA) who had localized renal cell carcinoma were evaluated for outcome prediction
using a clinical outcome algorithm previously shown to stratify patients into 3 risk groups
(low, intermediate, and high).  Validation was performed by comparing the 3 risk groups sepa-
rately within the 3 centers as well as by comparing the hazard ratios and concordance indices
amongst the 3 centers.
Results: Estimated disease-specific survival (DSS) rates at 5 years for the low-risk groups
were 94% (SR), 92% (MDA), and 93% (UCLA). The 5-year DSS rates for the intermediate-
risk groups were 65% (SR), 73% (MDA), and 78% (UCLA), while the rates for the high-risk
groups were 40% (SR), 30% (MDA), and 48% (UCLA). The concordance indices for each of
the databases were 79% (SR), 86% (MDA), and 84% (UCLA). 
Conclusions: A clinical algorithm that uses only 3 prognostic variables (1997 T stage, Fuhrman
grade, and performance status) to stratify patients with localized renal cell carcinoma into 3
risk groups has been shown to be applicable to external databases. This algorithm may be use-
ful for patient counseling, surveillance, and identification of high-risk patients for enrollment
into clinical trials.
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2.2 Introduction
The natural history of renal cell carcinoma (RCC) is complicated and influenced by numerous
factors [1]. Accurate prediction of the clinical outcomes of patients with RCC immediately
after resection of localized disease would be beneficial for counseling, follow-up evaluation,
and identification of high-risk patients potentially suitable for clinical trials. It has become
increasingly clear that the clinical behavior of RCC results from interactions amongst multiple
variables. As a result, nomograms and integrated staging systems have been developed to
improve the predictive capabilities of physicians.  Nomograms based on the Cox proportional
hazards model predict survivorship patterns for individual patients.  By comparison, staging
systems divide the patient population into subgroups where patients in different subgroups are
predicted to have different survival patterns.
In 2001, Memorial Sloan-Kettering introduced a postoperative nomogram which assigns
points based on a combination of variables that include histology, tumor size, 1997 T stage,
and whether the patient presented with symptoms [2].  In the same year, UCLA introduced the
UCLA integrated staging system (UISS) which combined 1997 TNM stage (I-IV), Eastern
Cooperative Oncology Group (ECOG) performance status (PS), and Fuhrman grade [3].
Subsequent to the introduction of the UISS, Zisman et al simplified the staging system into a
clinical outcome algorithm based on 1997 T stage, ECOG PS, and Fuhrman grade; this UISS
simplified algorithm resulted in 3 risk groups (low, intermediate, and high) for patients with
RCC [4].  More recently, Mayo clinic introduced the SSIGN prediction model based on 1997
TNM stage, tumor size > 5 cm, nuclear grade, and tumor necrosis [5]. The SSIGN model divi-
des patients into 10 different subgroups.
These predictive models may provide valuable information with regards to prognostic factors
associated with survival.  In this analysis, the UISS simplified outcome algorithm is applied to
patients from University Hospital St Radboud (Netherlands -177 patients), MD Anderson (399
patients) and an updated UCLA database (484 patients) in an effort to determine whether such
an algorithm can stratify patients from different institutions into distinct survival groups.  A
total of 1060 patients with clinically localized RCC who underwent nephrectomy were availa-
ble for evaluation of the outcome algorithm.
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2.3 Methods
A previously published outcome algorithm [3] was applied to databases from the St Radboud
(Netherlands), MD Anderson (MDA), and UCLA (updated database) in an effort to stratify
patients into distinct survival groups.  Briefly, stage was determined according to the 1997
UICC TNM classification of renal tumors [6]. Tumors were classified according to the
Heidelberg classification [7] and graded according to the Fuhrman grading scheme [8] by
pathologists from each of the 3 institutions.  Eastern Cooperative Oncology Group performan-
ce status (ECOG PS) was determined according to the original criteria set forth by Oken et al.
[9]. A total of 1060 patients from 3 institutions underwent radical or partial nephrectomy.  All
patients with localized disease who had no evidence of nodal involvement or metastatic spre-
ad were included from each center.  Risk groups were defined according to 1997 T stage,
Fuhrman grade, and ECOG PS.  A decision box was constructed (see appendix) to permit a
simple algorithmic assignment of patients into low intermediate, and high-risk groups.
Each of the databases from the institutions was updated in a retrospective manner. For all 3
institutions, the ECOG PS for each patient was determined at the time of office visit before
nephrectomy.
Disease-specific survival was determined by the Kaplan-Meier method and was calculated
from the date of nephrectomy to date of death or last follow-up.  Comparisons among groups
were performed by the log rank method to determine the significance of the Kaplan-Meier cur-
ves.
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St Radboud 
(N = 177) 
MD Anderson 
(N = 399) 
UCLA 
(N = 484) 
Mean age 59.6 58.1 61.5 
Males 121 (68%) 265 (66%) 309 (64%) 
Fuhrman grade 1  38 (21%)   25 (  6%) 101 (21%) 
Fuhrman grade 2  86 (49%) 152 (38%) 267 (55%) 
Fuhrman grade 3  43 (24%) 183 (46%) 100 (21%) 
Fuhrman grade 4  10 (  6%)   39 (10%)   16 (  3%) 
ECOG 0 165 (93%) 312 (78%) 282 (58%) 
ECOG 1   12 (  7%)   87 (22%) 197 (42%) 
T1   58 (33%) 157 (39%) 272 (56%) 
T2   32 (18%)   89 (23%)   69 (14%) 
T3   83 (47%) 153 (38%) 138 (29%) 
T4     4   (2%)     0     5   (1%) 
Low*   47 (27%)   78 (20%) 159 (33%) 
Intermediate* 119 (67%) 279 (70%) 255 (53%) 
High*   11  (6%)   42 (10%)   70 (14%) 
*: Risk groups are determined according to the simplefied clinical algorithm.
Table 1
Characteristics of patients with localized disease
A concordance index was calculated to determine the predictive ability of the algorithm using
the method introduced by Harrell et al. [10].  All pairs of patients from distinct risk groups
were considered where one member of the pair was known to have survived longer than the
other patient.  The pair was considered concordant with respect to the staging if the patient who
lived longer was in the lower risk group.  The concordance index is the percent of pairs that
are concordant.
A Cox model was used to determine the hazard ratios for the 3 centers considering the 3 risk
groups to be labeled as low, intermediate, and high-risk.  Data was analyzed using Stata 7.0
(College Station, TX).
2.4 Results
Table 1 lists the patient characteristics for the evaluated population with regards to sex distri-
bution, Fuhrman grade, ECOG PS, TNM stage, and T stage distribution.  Median follow-up
for each of the 3 groups was 63 (SR), 32 (MDA), and 33 (UCLA) months.  In addition, the
table also depicts the number of patients that are in each of the risk groups from each of the
respective institutions.
The decision box shown in appendix A can be used to determine the risk group of the patient;
this is done by starting at the top of the decision box and progressing downward through the
algorithm based on the patient's 1997 tumor stage, Fuhrman grade, and then ECOG PS.  After
the appropriate risk group has been determined, the patient's prognosis is then determined by
looking up the outcomes in table 2.
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Risk groups are determined according to the simplefied clinical algorithm
Risk group Survival St Radboud MDA UCLA 
Low 1-year 98% 98% 100% 
 3-year 94% 98% 95% 
 5-year 94% 92% 93% 
Intermediate 1-year 91% 97% 97% 
 3-year 77% 85% 87% 
 5-year 65% 73% 78% 
High 1-year 73% 80% 81% 
 3-year 44% 52% 58% 
 5-year 40% 30% 48% 
Table 2
estimated disease specific survival rates according to risk group in patients with localized disease
In order for a staging system to be applied and validated in a center, it is not necessary that the
survival curves be identical, but only that they result in clearly separated survivorship curves
at each respective center.  Figures 1a, 1b, and 1c depict the Kaplan-Meier curves for patients
with localized disease for the 3 risk group categories from each of the respective institutions.
The stratification trend across the 3 risk group categories for localized disease patients from
each of the institutions was statistically significant for disease-specific survival (DSS) (p <
0.001).  It is clear from each of the graphs that 3 distinctly separate survival curves result from
use of the clinical algorithm for patients from each of the respective institutions.
For a comparison between the centers, the predicted 1, 3, and 5-year disease-specific survivals
(DSS) for each of the 3 groups of patients stratified according to their risk group categories are
listed in table 2.  Estimated 5-year DSS for low-risk patients are 94%, 92%, and 93% for the
SR, MDA, and UCLA patients, respectively.  For the intermediate-risk patients, the rates are
65%, 73%, and 78% for SR, MDA, and UCLA, respectively.  High-risk patients have estima-
ted 5-year DSS rates of 40% (SR), 30% (MDA), and 48% (UCLA).
A concordance index was calculated to determine how accurate the clinical algorithm was at
placing patients into the correct risk group.  The concordance indices for each of the respecti-
ve institutions were 79%  (SR), 86% (MDA), and 83% (UCLA).Finally, hazard ratios and 95%
confidence intervals for each of the 3 institutions were determined to further compare the rela-
tionship of the 3 risk groups within each institution.  Patients in the SR group had a hazard
ratio of 2.54 (1.54 - 4.19); in other words, a patient in the intermediate-risk group had a 2.54
times likelihood of dying from RCC when compared to a patient in the low-risk group.  By
comparison, the hazard ratio for MDA patients was 4.39 (2.93 - 6.59), while the ratio for
UCLA patients was 3.15 (2.23 - 4.45).
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Figure 1
Kaplan-Meier curves for the patients  from each of the respective institutions.
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A, Kaplan-Meier curves for 177 patients from the University Medical Center Nijmegen with localized renal 
cell carcinoma.  Patients are stratified into 3 distinct survival curves based on low, intermediate, and high-risk 
characteristics. B, Kaplan-Meier curves for 399 patients from MD Anderson with localized renal cell 
carcinoma.  Patients are stratified into 3 distinct survival curves based on low, intermediate, and high-risk 
characteristics. C, Kaplan-Meier curves for 484 patients from UCLA with localized renal cell carcinoma. 
Patients are stratified into 3 distinct survival curves based on low, intermediate, and high-risk characteristics. 
2.5 Discussion
This clinical algorithm provides valuable information regarding survival after resection of
localized RCC by stratifying patients into low, intermediate, and high-risk groups.  As a result,
this algorithm accounts for the interaction of 3 well-accepted variables that affect survival.
This algorithm is easy to use and as illustrated in figures 1a, 1b, and 1c, provides statistically
significant stratification of patients into 3 risk groups and outcomes.  Staging systems differ
from nomogram models in that the latter predicts different survivorship outcomes for indivi-
dual patients. The staging of patients may be useful for evaluating clinical outcome, directing
therapy, assessing patient response to treatment, determining eligibility for entry into clinical
studies, and for interpreting results of clinical trials.
For several decades, published reports have emphasized the prognostic value of multiple fac-
tors for RCC such as stage, grade, and ECOG PS.  The clinical outcome algorithm used in this
study was used to generate 3 distinct risk groups applicable to an updated UCLA database and
also to two other institutions by combining the 3 prognostic factors listed above. 
This system allows physicians to confidently separate patients who undergo nephrectomy for
localized disease into different risk groups.  Information derived from the algorithm could be
used to determine whether a patient in the high-risk group should receive either adjuvant
immunotherapy or be enrolled into clinical trials.  Patients in the high-risk group have 5-year
DSS estimates of 40% (SR), 30% (MDA), and 48% (UCLA), suggesting that nephrectomy
alone may not be enough. 
By comparison, low-risk patients from each of the respective institutions have similar 5-year
DSS estimates of 94% (SR), 92% (MDA), and 93% (UCLA).  Patients in the low-risk group
may require less rigorous surveillance compared to their intermediate-risk or high-risk coun-
ter-parts.  This would likely decrease the number of computerized tomography scans, chest
radiographs, and amount of blood work performed in the low-risk group.  In turn, reductions
in potential nephrotoxic and allergic reactions to dye contrast would result; in addition, decre-
ased health care costs attributed to decreased surveillance testing would also result.
Other outcome models have been previously reported to predict survival in patients presenting
with localized disease and metastatic disease.  In 1988, Elson et al developed a scoring system
to determine prognosis for patients with advanced RCC that stratified patients into five groups
based on ECOG PS, time from diagnosis to metastasis, weight loss, prior chemotherapy, and
number of metastatic sites [11]. In 1995, Mani et al found that 5 prognostic factors (ECOG PS,
sarcomatoid histology, bone metastasis, weight loss, and absence of nephrectomy) could also
be combined to form low, intermediate, and high-risk groups [12].  More recently, Memorial
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Sloan-Kettering developed a model for patients with metastatic RCC that identified 5 different
pretreatment features as important prognostic factors as determined by multivariate analysis.
These factors included low Karnofsky score, anemia (hemoglobin < normal), high serum lac-
tate dehydrogenase (> 1.5 times normal), hypercalcemia (> 10 mg/dl), and absence of neph-
rectomy [13]. 
As significant as the above prognostic models are for predicting outcome for patients with
metastatic RCC, there remains a need for predicting clinical behavior after resection of locali-
zed RCC.  In 2001, Kattan introduced a postoperative nomogram that assigns points based on
histology, tumor size, 1997 P stage, and whether a patient presented with symptoms.  The
Kattan nomogram was designed to predict the 5-year probability of recurrence amongst
patients who undergo resection for localized RCC and assigns points based on the 4 factors
listed above.  It does not offer prognostic capabilities for predicting survival.  The purpose of
nomograms such as this is different than the subdivision of patients into a small number of sub-
groups.
The SSIGN (Stage, SIze, Grade, Necrosis) recently introduced by the Mayo Clinic [5] uses
1997 TNM stage, tumor size > 5.0 cm, Fuhrman grade, and evidence of necrosis to stratify
patients based on a point system as well.  With a mean follow-up of 9.7 years, the SSIGN
system stratifies patients into 10 survival curves.
The current algorithm used in this study is designed to separate patients into a small number
of risk groups. It combines 3 well-known prognostic factors into an easy-to-use decision box
(appendix) and then allows physicians to advise patients regarding 5-year survivals based on
3 distinct survival curves.  External data from 2 different institutions was used to validate this
algorithm, (figure 1).  The similarity of the high concordance indices seen for each of the 3
institutions suggests that this algorithm may be applicable to other external databases.  In addi-
tion, the survivorship curves for the 3 respective institutions demonstrate that each of the 3
subsets of patients within each institution can stratify survival for patients with localized dise-
ase into 3 distinct risk groups.
Limitations of this study include its retrospective nature and attendant issues routinely associ-
ated with such analyses.  Other limitations of this study include the lack of central pathology,
leading to concerns regarding interobserver reproducibility of grading.  However, personal
communication with pathologists from each of the 3 respective institutions confirmed that the
same criteria proposed by Fuhrman in 1982 were used at all three institutions.  Finally, simi-
lar to the other models described, the UCLA algorithm depends on postoperative variables,
thereby limiting its utility as a preoperative counseling tool.
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In conclusion, a clinical algorithm using 3 well-known prognostic factors can be used to pre-
dict survival and stratify patients undergoing nephrectomy for localized disease into 3 risk
groups. External data from 2 outside institutions suggest the validity of this algorithm with a
high concordance index. These risk categories can be used in clinical trial design and interpre-
tation as well as in clinical management areas such as surveillance.
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Appendix
Decision box to determine the appropriate risk category of patients with localized RCC
T Stage 1 2 3 4 
Fuhrman 
Grade 1-2 3-4 1 >1 
ECOG PS 0 ≥1 0 ≥1 
 
0 ≥1 0 ≥1 
 
Risk Group Low Intermediate High 
To obtain a risk group, begin at the top of the decision box and progress downward using patient 1997
American Joint Committee on Cancer T stage, Fuhrman grade and ECOG performance status at diagnosis.
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CHAPTER 3
VACCINATION OF PATIENTS WITH METASTATIC 
RENAL CELL CARCINOMA WITH AUTOLOGOUS 
DENDRITIC CELLS PULSED WITH AUTOLOGOUS 
TUMOR ANTIGENS IN COMBINATION WITH INTERLEUKINE-2:
A PHASE I STUDY
Published: J immunother. 2002 nov-dec;25(6):500-8.
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3.1 Abstract
Background: Dendritic cells (DC) have been recognized as the most potent antigen presenting
cells (APC) of the immune system and clinical trials with DC presenting tumor antigens have
shown promising results. We have previously shown that DC pulsed with autologous tumor
lysates derived from renal cancer can activate tumor specific cytotoxic T-lymphocytes.
Therefore, we performed a phase I study in patients with metastatic renal cell carcinoma, using
autologous DC loaded with autologous tumor lysate as a vaccine. The treatment was combin-
ed with a low-dose IL-2 therapy, as this has shown benefit in DC based therapies. 
Methods: DC were isolated from peripheral blood mononuclear cells (PBMC) of 12 patients.
The adherent PBMC were cultured in the presence of IL-4 and GM-CSF. Following seven
days of culture, the immature DC (iDC) were pulsed with the autologous tumor lysate derived
from tumornephrectomy specimens. Three vaccinations were given at two-weekly intervals as
intradermal single deposit injections. After each vaccination IL-2 was given to the patients for
5 consecutive days. In six patients, keyhole-limpet hemocyanin (KLH) was added to the DC
culture medium after four days as an immunogenic marker. Before and after the vaccinations
immunological and clinical monitoring was performed. 
Results: In all patients a primary tumor cell culture could be established and sufficient amounts
of tumor cells and tumor protein were obtained for vaccination purposes. We were able to
generate iDC. The phenotype of the DC for the first vaccination was in general dissimilar from
the phenotype of the DC for the last vaccination: most notably the number of CD14 positive
cells increased. Ovalbumin uptake remained high, substantiating high uptake capacity, under-
lining that these cells were still functional, immature DC. Proliferative responses against KLH
were observed, whereas proliferative responses against TuLy were absent. Humoral responses
against TuLy or KLH were absent. Clinical responses were not observed.
Discussion: This study shows the feasibility of a completely autologous DC and tissue cultu-
re methodology for the generation of tumor lysate pulsed DC. The vaccine, consisting of iDC
pulsed with autologous tumor lysate and KLH, was able to elicit anti-KLH responses, indica-
ting the ability of the injected DC to mount an immunological response. However, no cellular,
humoral or clinical anti-tumor responses were induced, suggesting that the vaccination strate-
gy with immature DC has little benefit for patients with advanced RCC. 
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3.2 Introduction
Renal cell carcinoma (RCC) is a relatively rare disease, comprising about 2% of all malignan-
cies [1, 2]. Approximately one-third of the patients present with metastatic disease (mRCC)
and after radical nephrectomy with curative intent, about 30% of patients develop recurrent
disease. mRCC does not respond to chemotherapy or radiotherapy [2]. Presently, interleukin-
2 (IL-2) [3] and/or interferon-alpha (IFN-a) [4] are the standard therapies for progressive
mRCC. However, the response rates are low (20%), with complete response rates of only 6%
[3]. Thus, once metastasized, the prognosis of mRCC patients is poor. One of the major rea-
sons for the ineffectivity of the standard immunotherapy approach might be lack of specifici-
ty of the agents given. Therefore new directions towards a more specific anti-tumor therapy-
strategy is of utmost importance.
Dendritic cells (DC) have been recognized as the most potent antigen presenting cells (APC)
of the immune system [5, 6]. The possibility to generate significant numbers of DC in vitro
with functional characteristics of potent APC [7, 8], has lead to the initiation of numerous cli-
nical trials exploring the efficacy of DC based vaccines, particularly after loading with pepti-
des derived from tumor-associated antigens.  Several studies have shown the feasibility of DC-
based vaccinations, e.g., in B-cell lymphoma [9], melanoma [10], RCC [11, 12], and prostate
carcinoma [13]. Up to 107 cells per vaccination have been used without any adverse side
effects or toxicity when administered intravenously or subcutaneously (s.c.). 
In a previous study we have shown that (tumor) specific cytotoxic T-lymphocytes (CTL) can
be induced by autologous DC pulsed with autologous tumor lysates (TuLy) in vitro [7].
Various studies have described the superiority of the combination of DC-based vaccines and
low-dose IL-2 [14, 15]. Based on these observations we performed a phase-I study to assess
the feasibility of vaccination with autologous DC loaded with autologous tumor lysate in com-
bination with IL-2 in patients with mRCC. 
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3.3 Patients & Methods
Twelve patients with mRCC with their primary renal tumor in place were enrolled in this study.
Baseline clinical data of the patients were acquired before vaccination. Inclusion criteria were
WHO performance status 0-2, over 18 years of age and capable of giving written informed
consent. Patients with CNS metastases, allergic diathesis, hypercalcemia, significant cardiac
problems, leukocytes < 2.0 x 109/l, platelets < 50 x 109/l, abnormal liver or kidney function
were excluded from the study.
The study was approved by the Ethical Board of the University Medical Center Nijmegen, The
Netherlands, in accordance with the current version of the declaration of Helsinki. 
Generation of dendritic cells.
DC were collected as described earlier [16]. In short, 1 week before vaccination fresh periphe-
ral blood mononuclear cells (PBMC) were obtained by differential centrifugation of auto-
logous heparin blood on Ficoll-Paque R plus gradients (Pharmacia Biotech, Alameda, CA,
USA). Cells were washed extensively in PBS (NPBI, the Netherlands) and suspended in 8 ml
XVIVO (Biowhittaker, Walkersville, MD, USA) supplemented with 2% heat-inactivated auto-
logous serum. PBMC were plated in 25 cm2 flasks (2.5-5 x 106 cells/ml) and incubated at
37oC for 60 minutes. The non-adherent cells were aspirated and discarded. The adherent cells
were gently rinsed with XVIVO (Biowhittaker) and cultured in XVIVO (Biowhittaker) sup-
plemented with 10% autologous serum, 800 U/ml human recombinant Granulocyte Monocyte
Colony Stimulating Factor (GM-CSF) and 1000 U/ml human recombinant Interleukin-4 (IL-
4) (Schering-Plough, Kennilworth NJ, USA). After 7 days, all cells in suspension and loosely
adherent cells were collected (see below).
In six patients, DC were pulsed with 70 ug Keyhole Limpet Hemocyanine (KLH)/flask 4 days
after initiation of every DC culture. Three days thereafter all cells in suspension and loosely
adherent cells were collected (see below).
Phenotyping of dendritic cells.
Cells were labeled with anti-CD14-FITC (DAKO, Marseille, France), anti-CD80-FITC, anti-
CD40-PE, anti-CD83-PE (Immunotech, Westbrook, ME, USA) and anti-CD86-PE
(Pharmingen, San Diego, CA, USA), respectively. After centrifugation and washing with PBS
the cells were fixed in 1% paraformaldehyde/PBS and analyzed by FACS analysis (Beckman
Coulter, Inc., Fullerton, CA, USA). 
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Preparation of the tumorlysate (TuLy). 
Immediately after tumornephrectomy, in the operation theater, approximately 30g tumor tissue
was minced and transferred to digestion medium containing 1 mg/ml Collagenase Type IV
(Sigma, St Louis, MO, USA), 0.1 mg/ml Hyaluronidase Type V (Sigma), 30 U
Deoxyribonuclease I Type IV (Sigma), 100U/ml Penicillin and 100ug/ml Streptomycin. After
overnight digestion at room temperature the suspension was sieved over a 200 um mesh to
remove the undigested fragments. This cell suspension was washed twice with PBS, applied
on a Ficoll-Paque R plus gradient and centrifuged. The cells at the interphase were collected,
washed three times with PBS and cultured in 75 cm2 flasks (0,5 x 106 cells/ml, 10 ml per
flask) in RPMI 1640 supplemented with 100U/ml Penicillin, 100ug/ml Streptomycin, 2 mM
Glutamine (complete medium), and 10% heat-inactivated autologous serum. After overnight
adherence the medium was changed. After the cells had reached 70% confluence, the tumor
cells were harvested by trypsinisation. Cells were resuspended in 5 ml PBS, irradiated (30 Gy),
washed with PBS and resuspended in 2 ml PBS. Thereafter the cells were subjected to three
freeze/thaw cycles, the protein concentration was determined (BioRad Laboratories B.V.,
Veenendaal, The Netherlands) and the obtained TuLy was aliquoted.
DC pulsed with TuLy.
TuLy (30ug/1 x 106 DC) was added to the DC (2-5 x 106 cells/ml) under serum-free condi-
tions, and the DC were incubated for 30 minutes at room temperature. Thereafter an equal
volume of complete medium containing 20% autologous serum was added, and DC were incu-
bated for 3 hours at 37oC. Subsequently, the cells were centrifuged and resuspended in 0.2 ml
saline for intradermal injection. 
Vaccination Schedule.
Vaccination started 3-5 weeks after the tumornephrectomy. DC were generated from freshly
obtained PBMC isolated 1 week before every vaccination. Three vaccinations were given at
two-week intervals as intradermal single deposit injections. Patients did not receive fixed
amounts of DC, but rather the total amount of DC isolated. Sterility of all vaccines was determ-
ined before administration. After each vaccination patients received IL-2 (Proleukin® (Chiron,
Emeryville, CA, USA)) 9x106U/day subcutaneous for 5 consecutive days by self-injection.
Clinical evaluation and follow-up.
Delayed type hypersensitivity (DTH) skin tests were performed at day 0 and day 42 (Multi
Test CMI, Aventis Pasteur SA Lyon, France). After each vaccination patients were evaluated
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according to the WHO Toxicity Criteria Scale. Baseline evaluation of tumor burden was asses-
sed before the tumor nephrectomy. Three weeks after completion of three vaccination cycles,
patients were evaluated by radiographic methods. Patients were followed at a 6 weeks interval
until disease progression.
T-cell proliferation assay.
PBMC were stimulated with KLH, TuLy, Candida Albicans, Tetanus toxoid (4 ug/2 x 105
PBMC) or IL-2 (20 IU/ml) in complete medium with 10% human AB serum (Biowhittaker).
On day 6 the cells were pulsed with 3H-thymidine for 16 hours and harvested. Experiments
were performed in triplicate. To cirvumvent assay-to-assay variation, all samples of one patient
were analyzed simultaneously. Data were expressed as stimulation index (SI), calculated as:
SI = counts per minute after vaccination / counts per minute at study entry
IFN-Gamma secretion ELISA.
ELISA plates (Falcon, Becton-Dickinson, San Jose, CA, USA) were coated with 100 ml anti-
human IFN-gamma monoclonal antibody (mAb, (Endogen, St Woburn, MA, USA) at
0,75ug/ml PBS overnight at 25oC. After blocking remaining protein binding sites for 1 hour
at 25oC with 1% gelatin/PBS (Sigma) plates were washed with PBS/(0.05%) Tween (Sigma).
Tissue culture supernatant of PBMC stimulated for 6 days were added and incubated at 25oC
for 1 hour. Plates were washed and incubated with biotin labeled anti-human IFN-gamma mAb
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Table 1
Patient characteristics
Patient Metastasis pT Grade Karnofsky Evaluation 
1 Lung 3a IV 90% SD 3.5 m* 
2 Liver, bone 3a III 80% PD* 
3 Lung, lymphoid organs 3b III 100% SD 5.0 m* 
4 Lymphoid organs 3b III 100% SD 18.0 m 
5 Lung, lymphoid organs 3a III 90% SD 4.0 m** 
6 Lung, lymphoid organs 3a II 100% SD 3.0 m 
7 Lung 3a II 100% PD 
8 Lung 2 II 90% SD 18+m 
9 Lung, adrenal gland 3a III 100% PD 
10 Bone, lymphoid organs 3b III 100% SD 12m 
11 Lung 3b II 100% SD 16+m 
12 Lung, bone, lymphoid organs 3a III 90% PD* 
*: Died of disease  **: Non-disease related death.
pT: Pathological stage; PD: progressive disease; SD: Stable disease.  
(Endogen), 0.2 ug/ml in 1% gelatin/PBS for 1 hour at 25oC. After washing, plates were incu-
bated with horseradish peroxidase labeled streptavidin (CLB, Amsterdam, Netherlands) dilu-
ted 1:15.000 in 1% gelatin/PBS for 30 minutes at 25oC. Plates were developed with 3,'3,5,'5-
tetramethanolbenzidine (TMB) in 0.1 M acetatebuffer pH 5.5/ 0.03% H2O2 for 20 minutes at
room temperature in the dark. Absorbance was measured at 450 nm.
Analysis of humoral immune response.
ELISA plates (Falcon, Becton-Dickinson) were coated with 100ul KLH (20 ug/ml) or TuLy (1
ug/ml) overnight at 4oC. Plates were blocked for 2 hours with 1% gelatin/PBS at 25oC. After
washing with 0.05% PBS/Tween, plates were incubated with serial dilutions of patient sera
obtained before, during and after treatment, for 1 hour at 25oC. After washing, plates were
incubated with peroxidase labeled goat-antihuman Ig (Sigma) in 1% gelatin/PBS. Plates were
developed, and absorbance was measured as previously described.
3.4 Results
Between February 1999 and February 2000, 12 patients of the Kidney Cancer Clinic of the
Urology and Medical Oncology Department of the University Medical Center Nijmegen, The
Netherlands, were included in the protocol. All patients signed an informed consent before
study entry. The characteristics of the 12 patients are listed in table 1. Enrolled were 8 men and
4 women with a median age of 55 years (range: 43-69). Performance state was > 80% accor-
ding to Karnofsky. Pathological assessment of the primary RCC tumors showed that all
patients but one (Pt 11: chromophilic) had RCC tumors of the clear-cell type.
Vaccine preparation.
A primary cell culture could be established from all radical tumornephrectomy specimens and
sufficient amounts of tumor cells (mean: 2.6x108, range: 0.4-9.7x108) and tumor protein
(mean: 3.6 mg, range: 1.4-7.2 mg) were obtained for vaccination purposes. Phenotypic analy-
sis showed that the cells harvested were predominantly cytokeratin positive, confirming out-
growth of tumor cells and minimal contamination of fibroblasts. In general, tumor cells were
harvested 3 weeks after establishment of the primary culture for TuLy preparation.
The yield of PBMC and the characteristics of the generated DC are listed in tables 2 and 3.
In this protocol, DC were generated from freshly obtained PBMC, isolated one week before
every vaccination. In general, the yields of PBMC and, to a lesser extend, the number of iso-
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lated DC, increased at subsequent blood drawings. The yield of PBMC and DC increased from
an average of 78 x 106/ 9 x 106 cells at the first blood draw to an average of 131 x 106/ 15 x
106 cells respectively at the third blood draw (table 2). In most testcultures we were able to
generate DC of an immature phenotype (CD14low, CD86high, CD80low, CD40high,
CD83low: fig. 1). The phenotype of the DC for the first vaccination was, in general, dissimi-
lar from the phenotype of the DC for the last vaccination. CD86 and CD40 remained high and
CD83 remained low, but the number of CD14 positive cells increased (table 3).
In selected cases, CD11c phenotype was determined, and, under the culture conditions used in
this trial, all cells were CD11c+. Thus, CD11c did not provide extra information on the pre-
sence of non-DC cells or DC phenotype. Despite this unusual phenotype, these DC still exhi-
bited high uptake capacity, as determined by FITC-ovalbumin uptake, substantiating that these
cells were still functional, immature DC.
Immunological monitoring.
Analysis of proliferative responses of PBMC obtained at various time points during and after
completion of the vaccination did not reveal any measurable response against TuLy in any of
the patients. In contrast, almost all patients showed strong proliferative responses against
Candida Albicans or Tetanus toxoid, two recall antigens. Moderate proliferative responses of
PBMC against KLH were observed in patients vaccinated with DC loaded with KLH and TuLy
translating to moderate stimulation indices (fig. 2). In concordance with the T-cell prolifera-
tion, KLH stimulation resulted in a low specific IFN-gamma secretion (data not shown).
Humoral responses against TuLy or KLH were absent.
Before the vaccinations, nine of the twelve patients had a DTH response against more than one
 Vaccination 1 Vaccination 2 Vaccination 3 
Yield of PBMC       (*106) 78    (34 - 140) 99    (65 - 133) 131    (80 - 225) 
Yield of PBMC/ml  (*106) 0.8   (0.4 - 1.4) 1.0   (0.7 - 1.2) 1.4     (0.9 - 2.4) 
Yield of DC             (*106) 9.1   (2.4 - 17.0) 15    (4- 34) 14.6   (4.0 – 36.0) 
Yield of DC/ml        (*106)  0.09 (0.03 - 0.19) 0.15 (0.04 - 0.34) 0.15   (0.04 - 0.36) 
 
Table 2
Average yield of peripheral blood mononuclear cells and dendritic cells of the 12 patients.
 CD14+ CD86+ CD40+ CD80+ CD83+ 
testculture 2 99 99 7 10 
1e vaccine 1 94 93 7 11 
2e vaccine 13 93 98 4 2 
3e vaccine 30 95 98 8 6 
 
Table 3
Dendritic cell phenotyping of a representative patient.
Numbers represent the percentage of positive cells.
of the eight recall antigens used. One patient developed a DTH response against a recall anti-
gen after the vaccination, whereas there was no response prior to the vaccinations. In five
patients the response to the number of recall antigens increased. None of the patients showed
a DTH response to the tumor lysate before or after the vaccinations.
Clinical observation.
The treatment was well tolerated, and no significant side effects were seen. Transient erythe-
ma and/or induration at the site of the injection was observed in five patients. Patients expe-
rienced typical side effects of low-dose s.c. IL-2 treatment: moderate fever, chills and fatigue.
Side effects were not enhanced by the addition of DC vaccination. Toxicity was < grade 2, and
did not lead to treatment discontinuation. Four patients showed progressive disease at the first
clinical evaluation after treatment (3 months). In one of these patients pulmonary metastases
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The DC were stained with antibodies specific for CD14, CD80, CD40, CD83 and CD86 and analyzed on a
flow cytometer. Consistent with the phenotype of immature DC, the cells expressed low levels of CD14 and
CD83 and high levels of CD86 and CD 40. The percentage of cells expressing particular cell surface markers
is shown in appropriate quadrants.
Figure 1
Phenotype of a7-day autologous immature dendritic cell test culture
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Figure 2:
Analysis of proliferative responses of peripheral blood mononuclear cells (PBMC)
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Analysis of proliferative responses of peripheral blood mononuclear cells (PBMC) at various time points during
after completion of the vaccination. Two hundred thousand PBMC were stimulated  for 6 days with TuLy, KLH
or Candida Albicans, respectively. On the 6th day, the cells were pulsed with [3H]thymidine for 16 hours, after
which the proliferation was measured. Data were expressed as stimulation index (SI), i.e. [3H] counts per minu-
te after vaccination/[3H] counts per minute at study entry; lines represent mean SI. Each marker represents an
individual patient; 1st vac (2 weeks after 1st vaccination); 2nd vac (4 weeks after 1st vaccination); 3rd vac (6
weeks after 1st vaccination); post (3 months after last vaccination)
were removed (Pt 7). This patiënt is still free of disease. In six patients disease progression was
observed after a mean period of stable disease of 7.6 months (range 3.0 - 18.0 months). Two
patients (Pt 8 & 11) are still stable with a mean period of 17.0 months (range 16+ - 18+
months). In one patient pulmonary metastases were removed. This patient is now still free of
measurable lesions. One non-disease related death occurred in a patient with stable disease (6
months). No partial or complete responses were seen (table 1).
3.5 Discussion
To study the potential role of DC-TuLy-based vaccines as therapy for patients with advanced
RCC we performed a phase-I clinical trial with DC loaded with tumor lysate in combination
with IL-2. The influences of allogeneic or autologous culture conditions of DC and the use of
allogeneic or autologous tumor tissue on the efficacy of DC vaccination are unknown.
Therfore, we choose a completely autologous setting, Because this enables appreciation of
immune responses without interference of , e.g., bystander effects, reactivity against minor
anigens, etc., through the use of allogeneic cells. We have previously shown  the feasibility  to
generate autologous DC able to induce CTL with strong autologous tumor cell-killing capaci-
ty in vitro [7]. Furthermore, Shimizu et al. [14], and Rosenberg et al. [15] demonstrated that
low dose IL-2 can potentiate the anti-tumor effect of TuLy pulsed DC in vivo and Höltl et al
[11], showed induction of cellular and humoral immune responses in patients with advanced
RCC after vaccination with mature dendritic cells pulsed with TuLy. The latter was a clean
illustration that immunogenic structures might be present on autologous RCC. Our use of
immature DC was based on the observation that antigen-uptake capacity of immature DC is
superior over uptake capaciry of mature DC [17]. In view of our pulsing strategy, maximal
uptake capacity seemed to be essential. These observations formed the foundation of this phase
I clinical trial with autologous, immature DC, pulsed with autologous TuLy in combination
with a low dose IL-2 regimen similar to Rosenberg et al. [15]. Recently, Fong et al. [18] sho-
wed clear evidence that intradermally injected DC  might mature in vivo , i.e., the use of imma-
ture DC does not appear disavantageous.
In all patients and for all vaccinations, significant numbers of DC were obtained. Not unex-
pectedly, administration of low dose IL-2 led to increased numbers of PBMC harvested. In
parallel, we observed a similar increase in DC numbers generated. It is well documented that
IL-2 administration results in T cell proliferation [19], but the influence of biological respon-
se modifiers on the development of DC from PBMC still needs to be clarified. In our trial the
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phenotypic profile of the DC cultured at vaccine initiation differed from the phenotype of DC
cultured for the last vaccination (table 3). This may be the result of the application of IL-2 and
its effect in vivo. This is in line with the observations of Merad et al [20] who investigated the
phenotypic modulations of DC during the treatment with IL-2/IFN-alpha or IL-12 in patients
with mRCC. They found that PBMC from these patients maintained the ability to differentia-
te into functional DC, without selective quantitative or qualitative advantage [20]. Despite this
somewhat different phenotype, protein-uptake experiments demonstrated high protein uptake
capacirt, confirming that these cells were still functional, immature DC. Because it is unclear
whether the number of injected DC correlates with immunologic and clinical responses,
Patients received the entire amount of cultured DC generated.
In melanoma, many vaccination trials have been performed with peptide loaded DC (reviewed
in [21]). This was based on the isolation of CTL directed against various melanoma-associa-
ted antigens from PBMC of patients with melanoma, suggesting that these antigens can serve
as CTL targets. In human RCC, however, only a few specific tumor antigens, such as G250
and RAGE [22, 23], are known. RAGE, being expressed in a minor percentage of RCC is, the-
refore, a suboptimal target. G250 is expressed in the majority of RCC, and an HLA-A2.1-
restricted epitope recognized by CTL is present in this protein [24]. However, G250-specific
CTL could not be isolated from TIL of patients with RCC [22]. Thus, it is unclear whether this
antigen is a suitable T cell target. In the absence of clearly defined potentially immunogenic
peptides, we pursued vaccination with tumor-extract pulsed DC. This strategy can lead to dra-
matic anti-tumor responses (e.g. [25]), and circumvents the requirement of using identified
tumor specific or tumor-associated antigens. Furthermore, multi-antigen loaded DC are likely
to give poly- or oligoclonal expansion of T-cells, which might have an enhanced antitumor
effect in comparison to peptide-pulsed DC. Nevertheless, despite the use of complete TuLy, no
immunologic response was measurable in any of the patients. This is in contrast with the
results of Höltl et al [11] who used intravenously infused mature DC pulsed with TuLy and
KLH. These investigators were able to detect cellular and humoral responses against TuLy. It
is possible that this difference is due to our use of immature DC.
In addition to the significance of IL-2 supplementation and pulsing with TuLy instead of well-
defined peptides, the route of administration and maturation status are also of importance.
Patients received intradermal injections based on reports that DC distribution to sites of lym-
phoid tissue is dramatically influenced by the route of administration and that intradermal
injections appear to result in migration to regional lymph nodes and are qualitatively superior
[18, 26]. TuLy was pulsed immediately before DC administration, taking advantage of the abi-
lity of immature DC to effectively capture antigens [17,27,28]. Theoretically, mature DC
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might be preferable for the initiation of a powerful anti-tumor response. They may exhibit
superior migration characteristics [29], although this has been disputed [30]. Additionally,
mature DC are superior in antigen presentation and priming of naïve T cells [8], in particular
because upregulation of MHC class I and II expression and co-stimulatory molecules occurs.
Moreover, they acquire the ability to produce IL-12 and become potent initiators of both a pri-
mary and a secondary T-cell response [17]. However, Barratt-Boyes et al [30] documented that
the state of maturation at the time of injection had no influence on the proportion of DC that
localized to draining lymphoid organs, as labeled immature and mature DC were detected in
equal numbers. These investigators concluded that in vitro maturation is not a requirement for
migration of the DC from the injection site to lymphoid organs. They suggested that the use of
immature DC loaded with TuLy undergoing natural maturation in vivo might be preferred over
in vitro maturation [30]. In view of the superior protein uptake capacity, similar migration cha-
racteristics of immature DC over mature DC, the uncertainty of appropriate in vitro matura-
tion methods, as well as evidence that intradermal injected immature DC can mature in vivo,
immature DC were used. In our study, cellular immune responses against TuLy were not obser-
ved, whereas anti-KLH responses were moderate. In addition, humoral immune responses
against TuLy and KLH were completely absent. Although this indicates that the administered
immature DC were functionally capable of inducing only a minimal immune response, this
response was much lower than the response described by Höltl et al. [11] who used intrave-
nously infused mature DC pulsed with TuLy and KLH. In twelve patients with mRCC  a strong
cellular and humoral immune response against KLH waas detected and additionally, cellular
and humoral responses were detected against TuLy, albeit at a lower level [11]. Thus, the matu-
ration status of DC seems to be of utmost importance, and it appears preferable to pulse imma-
ture DC with TuLy followed by in vitro maturation for the induction of a powerful immune
response.
Simons et. al. [31] used GM-CSF transduced autologous tumor cells to induce antitumor res-
ponses in patients with RCC. This study was based on extensive animal experimentation sho-
wing that vaccines consisting of GM-CSF transduced tumor cells were superior inducers of
antitumor responses [32] possibly through eosinophils. Indeed marked infiltration ofeosinop-
hils was observed in DTH sites of patients with RCC, and one patient showed a partial clini-
cal response. the rationale of our DC study and the GM-CSF vaccine study are fundamentally
different. Although the diversity of RCC antigens is similar, we have loaded DC with tumor
proteins ex-vivo, whereas Simons et. al. [31] aimed at in vivo activation of APC. Different
effector cells seem to be involved, and the circumstances of antigen presentation differ.
Therefore these trials are difficult to compare.
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Unfortunately, there is no consensus in the literature as to the appropriate/optimal vaccine
dose. Tumor load, immunologic status, and tumor type are all parameters that are likely to vary
between patints and influence the effects of DC vaccination. Therefore, in general, investiga-
tors tend to inject as many DC as possible, the strategy used here being that all DC harvested
are injected, divided over several intradermal deposits. the biweekly vaccination schedule was
realistic from a logical (patient) standpoint, as well as from an immunologic standpoint. In
view of the lack of knowledge of (potential) CTL targets and their immunogenicity, little could
be tuned with regards to the dosing and timing schedule.
To our knowledge, the sufficient dose of tumor cells/protein has not been determined in any
comparable study. We based the amount of protein pulsed on DC on our earlier results where
30ug/106 DC was suffucient for the induction of CTL able to kill autologous RCC celss [7].
Clearly, this amount was insufficient  for the induction of immune responses in the vaccinated
patients with mRCC. It is unlikely that this failure is the consequence of the amount of pulsed
protein. Remarkably, a pulse with 20 ug KLH/1x106 cells induced only a very moderate anti-
KLH response, and, therefore, it is likely that the failure to induce anti-tumor immune respon-
ses is caused by the use of immature DC. This conclusion is supported by recent results of
Jonuleit et al. [33] who reported that immature DC can induce the development of IL-10 pro-
ducing non proliferating T-cells. Furthermore, these T-cells lost their ability to produce IFN-
gamma, IL-2 and IL-4. Possibly, induction of such cells can explain why CTL responses
against TuLy were absent, and responses against KLH were only moderate. 
Despite the addition of IL-2 no objective clinical responses were observed. This contrasts to
the results of Shimizu et al1 [14] and Rosenberg et al [15] who describe a positive effect of the
combination of IL-2 with specific immune therapy. Nevertheless, in eight of twelve patients
with mRCC, treated with surgery, DC vaccination and IL2, stabilization occurred. This stabi-
lization might be the effect of vaccination. Recently, several investigators have also explored
the use of DC based vaccines for patients with mRCC [11, 12]. Höltl et al. [11,34] used intra-
venously infused mature DC pulsed with TuLy with one out of four patients responding
[11,34]. Gitlitz et al [35] treated mRCC patients with immature DC pulsed with TuLy/lipos-
omes. In one patient changes in immunological parameters were observed, as well as a short-
lived partial response. The poor clinical response rates showed that this potentially new treat-
ment needs to be optimized. In this regard the study of Kugler et al. [12] who evaluated a vac-
cine using tumor cell/DC hybrids is of interest. These investigators used electrofused auto-
logous tumor cells in combination with allogeneic DC, resulting in impressive (41%) clinical
response rates. Interestingly, their results indicated that electrofused RCC/DC hybrids can eli-
cit HLA restricted T cell responses with potent anti-tumor response.
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In conclusion, the current study demonstrates that it is feasible to generate a DC-based vacci-
ne in a completely autologous setting. The observation that this vaccine, consisting of imma-
ture DC pulsed with autologous TuLy and KLH in combination with IL-2 was able to elicit
anti-KLH responses, showed that the injected DC were functional. Nevertheless, the immune
responses were minor, and immune responses against tumor antigens were not observed, indi-
cating that this vaccination strategy was suboptimal. Clinical benefit is minimal; emphasizing
that further optimization is needed. Currently, trials investigating the effect of mature DC/
RCC hybrids in the treatment of renal cell carcinoma patients are in progress.
Acknowledgemnts:
The authors thank Carl G. Figdor, PhD, and Nicole Scharenborg, Tumor Immunology
Laboratory, Nijmegen, The Netherlands, for their contributions.
65
Vaccination of mRCC patients with DC and IL-2
References
1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. New. Engl. J. Med. 1996;335:865.
2. Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D, et al. Renal cell carcinoma: 
recent progress and future directions. Cancer Research 1997;57:5189.
3. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the tre
atment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 
or high-dose interleukin-2 alone.New. Engl. J. Med. 1987;316(15):889-97.
4. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon-a2a in metastatic renal
cell carcinoma: an outpatient multicenter trial. J. Clin. Oncol. 1993;11(9):1809-16.
5. Melief CJM. Dendritic cells as specialized antigen-presenting cells. Res. Immunol. 1989;140(9):902-
906, Discussion 918-26.
6. Steinman RM. The dendritic cells system and ite role in immunogenecity. An. Rev. Immun. 1991;9: 271-
96.
7. Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, et al. Presentation of renal tumor antigens 
by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implica
tions for live kidney cancer vaccines. Clin. Cancer Res. 1999;5(2):445-54.
8. Thurnher M, Papesh C, Ramoner RGastl G, Bock G, Radmayr C, et al. In vitro generation of CD83+ 
human blood dendritic cells for active tumor immunotherapy. Exp. Hematol. 1997;25(3):232-7.
9. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell
lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996;2(1):52-8.
10. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, et al. Induction of antigen-
specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed 
autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 1995;92(17):8078-82.
11. Höltl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H. et al. Cellular and humoral immune res
ponses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic 
cells. J.Urol. 1999;161:777-782.
12. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metasta
tic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 
2000;6(3):332-336.
13. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate can
cer using autologous dendritic cells pulsed with HLA-A2.1-specific peptides from prostatic specific 
membrane antigen. Prostate 1996;29(6):371-80.
14. Shimizu K, Fields RC, Giedlin M, Mulé JJ. Systemic administration of interleukin-2 enhances the the
rapeutic efficacy of dendritic based vaccines. Proc. Natl. Acad. Sci. USA 1999;96(5):2268-73.
66
Chapter 3
15. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic
and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic 
melanoma. Nat. Med. 1998;4(3):321-7.
16. Kiertscher SM, Roth MD. Human CD14+ leukocytes acquire the phenotype and function of antigen-pre
senting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996 Feb;59(2):208-18.
17. Larsson M, Majeed M, Ernst D, Magnusson KE, Stendahl O, Forsum U. Role of annexins in endocyto
sis of antigens in immature human dendritic cells. Immunology 1997;92(4): 501-11.
18. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG: Dendritic cells injected via different routes indu
ce immunity in cancer patients. J. Immunol. 2001;166:4254-9 
19 Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer 
patients: decreased delayed type hypersensitivity response and decreased proliferative response to solu
ble antigens. J. Clin. Oncol. 1988;6(9):1440-9.
20. Merad M, Angevin E, Wolfers J, Flament C, Lorenzi I, Triebel F, et al. Generation of monocyte-derived
dendritic cells from patients with renal cell cancer: modulation of their functional properties after thera
py with biological response modifiers (IFN-alpha plus IL-2 and IL-12). J.Immunother. 2000;23(3):369-
78.
21. Schadendorf D, Nestle FO: Autologous dendritic cells for treatment of advanced cancer -an update. 
Recent Results Cancer Res. 2001;158:236-248 
22. Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH et 
al.: Molecular cloning and immunogenicity of renal cell carcinoma associated antigen G250. Int. J. 
Cancer 2000;85:865-870 
23. Gaugler B, Brouwenstein N, Van Tomme V, Szikora JP, Van der Spek CW, Patard, JJ et al.: A new gene
coding for an antigenrecognized by autologous cytolytic T lymphocytes on a human renal carcinoma. 
Immunogenetics 1996;44:323-330
24. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, Adema GA: The renal cell
carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope
recognized by cytotoxic T Lymphocytes. Cancer Res. 1999;59:5554-9 
25. Nair, S.K., Snyder, D. Rouse, B.T. and Gilboa, E.Regression of tumors in mice vaccinated with proffe
sional antigen-presenting cells pulsed with tumor extracts. Int.J.Cancer 1997;70:706-715 
26. Morse MA, Coleman E, Akabani G, Niehaus N, Coleman D, Lyerly HK: Migration of human dendritic
cells after injection in patients with metastatic malignancies. Cancer Res. 1999;59:56-58 
27. Sallusto F, Lanzaveccia, A. Efficient presentation of soluble antigens by cultured human dendritic cells
is maintained by Granulocyte/Macrophage Colony-stimulating factor plus Interleukin-4 and down-regu
lated by Tumor Necrosis Factor-a. J. Exp. Med. 1994;179(4):1109-18.
28. Mellman IS, Plutner H, Steinman RM, Unkeless JC, Cohn ZA. Internalization and degradation of macro
67
Vaccination of mRCC patients with DC and IL-2
phage Fc receptors during receptor-mediated phagocytosis. J. Cell. Biol. 1983;96(3): 887-95.
29. Banchereau J, Steinman RM. Dendritic Cells and the control of immunity. Nature 1998;392(6673): 245-
52.
30. Barratt-Boyes SM, Zimmer, MI, Harshyne LA, Meyer EM, Watkins SC, Capuano S 3rd, et al. 
Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic 
cell-based vaccines.  J. Immunol. 2000;164(5):2487-95.
31 Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vac
cines generated by ex vivo granulocyte macrophage colony-stimulating factor gene transfer. Cancer Res.
1997Apr 15;57(8):1537-46. 
32 Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete muri
ne granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-
tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43.
33. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonprolifera
ting CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human
dendritic cells. J. Exp. Med. 2000;192(9):1213-22.
34. Höltl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M. CD83+ blood dendritic cells as a vac
cine for immunotherapy of metastatic renal-cell cancer. Lancet 1998;352:1358-1360.
35. Gitlitz B, Hinkel A, Mulders P, Tso CL, Moldawer N, Figlin R et al. A. Multi-antigen loaded dendritic 
cell vaccine for the treatment of metastatic renal cell carcinoma: in-vitro correlates. J. Urol. 1999;161(4
suppl.):1-457. Abstract 522.
68
Chapter 3
69
Vaccination of mRCC patients with DC and IL-2
70
CHAPTER 4
VACCINATION OF PATIENTS WITH PROGRESSIVE 
RENAL CELL CARCINOMA WITH CA9-PEPTIDE 
PULSED MATURE DENDRITIC CELLS
Accepted for publication in the Journal of Immunotherapy.
71
72
Chapter 4
4.1 Abstract
Introduction: Carbonic Anhydrase-IXG250/MN (CA9) is a renal cell carcinoma (RCC)-asso-
ciated antigen ubiquitously expressed in the clear-cell subtype of RCC. Two CA9-derived pep-
tides have been identified defining a CTL epitope and HLA-DR epitope respectively able to
induce T cell responses in vitro. A phase-I clinical trial was performed with CA9-peptide loa-
ded dendritic cells in patients with progressive, cytokine-refractory metastatic renal cell car-
cinoma to assess the safety, toxicity and induction of CA9-specific immunity.
Methods: Patients with objective progressive metastatic RCC received 5 vaccinations of matu-
re dendritic cells (mDC) pulsed with the CA9-derived peptides and KLH. Peripheral blood was
collected at regular intervals, delayed-type hypersensitivity (DTH) was tested at baseline and
after the last vaccination and skin biopsies of positive DTH-sites were collected for immuno-
monitoring purposes. Patients were also monitored for clinical responses.
Results: No significant toxicity was observed. In all patients humoral responses were observed
against KLH, as well as DTH conversion. Evaluation of biopsy material suggested increased
influx of T-helper cells. In none of the immunomonitoring assays evidence for the induction of
CA9-peptide specific immunity was observed. No clinical responses were observed.
Conclusion: The vaccination of DC-pulsed with KLH and two CA9 derived peptides was well
tolerated. The lack of induction of CA9-peptide specific immune responses indicate that this
particular peptide combination cannot induce peptide-specific immune responses.
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4.2 Introduction
Patients with metastasized renal cell carcinoma (mRCC) have a poor prognosis. Radio- and
chemotherapy are not effective [1,2]. Experimental treatments currently under investigation
include anti-VEGF monoclonal antibody Bevacizumab, small molecule receptor tyrosine kina-
se inhibitor Sutent (SU11248), and targeting the Raf kinase pathway Sorafenib (BAY 43-9006)
[3-6]. At present cytokine based therapy is the only registered treatment for mRCC with the
ability to induce long-term responses, albeit in a minority of patients [7].
In view of the non-specific character of these cytokine regimens, methods to induce more spe-
cific immune responses against RCC are under investigation. Dendritic cells (DC) have been
identified as the most potent antigen presenting cells of the immune system [8] and collective
results of DC-based clinical trials have demonstrated the safety and feasibility of this appro-
ach [9,10]. In the development of effective DC-based vaccines knowledge of potentially
immunogenic structures is of importance. In RCC, the RCC-associated antigen Carbonic
Anhydrase-IXG250/MN (CA9) was identified [11]. CA9 is present in >95% of the clear-cell
subtype of RCC. Moreover, no expression can be detected in the majority of normal tissues,
including normal kidney tissue. Expression in other normal tissues is limited to large bile ducts
and gastric epithelium [12]. Previous studies have identified a MHC class I and MHC class II
CA9-derived peptide and confirmed their potential immunogenicity in vitro [13,14]. These fin-
dings, together with the high prevalence of CA9 in RCC appear to make these peptides poten-
tial candidates for peptide-pulsed DC vaccination to induce both CD4+ and CD8+ RCC spe-
cific T-cells. Therefore, we tested whether vaccination of CA9 peptide loaded DC of progres-
sive mRCC patients resulted in CA9 specific immunity.
4.3 Patients & Methods
Patient Selection
Patients with cytokine refractory and progressive mRCC of the clear cell subtype were enrol-
led in the study protocol. Inclusion criteria were HLA-A2.1+ and HLA-DR+, WHO perfor-
mance status 0-1, over 18 years of age and capable of giving written informed consent. Patients
with CNS metastases, allergic diathesis, hypercalcemia, significant cardiac problems, leuko-
cytes < 2.0 x 109/l, platelets < 50 x 109/l, abnormal liver or kidney function were excluded
from the study. The study was approved by the Ethical Board of the University Medical Center
Nijmegen, in accordance with the current version of the declaration of Helsinki. All patients
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signed an informed consent form before entering the study protocol.
Study Design
Patients received 5 intradermal vaccinations in week 1, 2, 3, 6 and 12 respectively. Patients
received an approximate one-fifth of the DC yield pulsed with the two peptides. Medical histo-
ry was recorded at baseline and medical performance was recorded at every visit. Standard
blood test, urine analysis and blood draw of peripheral blood for immunological monitoring
was performed at baseline and weeks 4, 7, 13, and 16. Radiological assessment was performed
4 weeks after the last vaccination. Delayed type hypersensitivity (DTH) skin testing was per-
formed one week before the first vaccination and at week 4 and 13. When redness and indura-
tion was induced, a 6mm skin biopsy was performed 48 hours after the DTH skin testing per-
formed at week 13.
Carbonic Anhydrase-IXG250/MN-derived peptides
HLA-A2.01-restriction (nonamer): 254-262 (CA9p254, HLSTAVARV) 
HLA-DR-restriction (20-mer): 249-268 (CA9p249,  IHVVHLSTAVARVDEALGR)
The CA9-derived peptides were manufactured, vialed and distributed by Clinalfa AG,
Switzerland, under GMP conditions, approved for clinical use. The product was supplied as
sterile, pyrogenfree lyophilized material  aliquoted in 200 ug amounts. The purity of the pep-
tide was >95% (HPLC).
Generation and Pulsing of Dendritic Cells
A concentrated leukocyte fraction was generated through leukapheresis, processing 6 liters of
blood. Peripheral blood mononuclear cells (PBMC) were obtained by differential centrifuga-
tion of the leukocyte fraction on Ficoll-Paque R plus gradients (Pharmacia Biotech, Alameda,
CA). Cells were washed extensively in PBS (NPBI, the Netherlands) and suspended in DC
medium: XVIVO-15 (Biowhittaker, Walkersville, MD) supplemented with 2% heat-inactiva-
ted pooled human AB serum (HAB, Bloodbank Rivierenland, Nijmegen, The Netherlands).
PBMC were plated in 225 cm2 flasks (10x106 cells/ml, 30 ml/flask), and incubated at
37oC/5%CO2 for 60 minutes. The non- and loosely adherent cells were aspirated. The adhe-
rent cells were cultured in complete DC culture-medium (DC medium supplemented with 800
U/ml human recombinant Granulocyte Monocyte Colony Stimulating Factor (GM-CSF) and
500 U/ml human recombinant Interleukin-4 (IL-4), both Schering-Plough, Kennilworth NJ)).
At day 4, cells were transferred to 6-well plates in 2ml of complete DC culture-medium
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(0.5x106 cells/ml) and Keyhole Limpet Hemocyanine (KLH; Calbiochem, San Diego, CA,
USA) was added (25 ug/ml). For monitoring purposes a small amount of DC were plated wit-
hout the addition of KLH. The immature DC were matured at day 6 for 48 hours. One ml of
complete DC culture medium was added to the 6-wells with the inclusion of tumor necrosis
factor-alpha (TNF-alpha; Sigma Aldrich, Dorset, U.K.), final concentration 20ng/ml, and
prostaglandin-E (PGE-2; Prostin E2, Pfizer, The Netherlands), final concentration 0.35 µg/ml.
DC were harvested and frozen at -1400C until use (107 cells/vial). On the vaccination day DC
were thawed, resuspended in XVIVO-15, divided in two equal amounts and pulsed with
CA9p254 or CA9p249 respectively. DC were pulsed for 90 minutes at 37 °C/5% CO2 (75
µg/ml), fresh peptides were added (125 µg/ml), and DC were kept at room temperature for 90
minutes. After peptide pulsing DC were pooled and prepared for vaccination (final injection
volume 400 µl).
DTH skin testing
DTH skin testing with (a) PBS, (b) KLH (5mg/injection), (c) the CA9p254 peptide and the (d)
CA9p249 peptide (100mg peptide/injection) was performed at baseline. At week 4 and 13
DTH skin testing was repeated, with the addition of (e) unpulsed DC, and DC pulsed with (f)
KLH, (g) KLH plus CA9p254 and (h) KLH plus CA9p249 (2.5x105 DC/injection).
At week 13, 2 days after the skin testing, a biopsy was taken of normal skin together with posi-
tive DTH sites. Biopsies were divided for immunohistochemical evaluation and expansion of
DTH infiltrating lymphocytes (DIL). Tissue was cultured in RPMI 1640 supplemented with
5% HAB and recombinant IL-2 (100 U/ml) for 3-4 weeks. On day 7, 14 and 21 half of the
medium was replaced by fresh IL-2 containing medium. At several time points during cultu-
re, supernatant was collected and stored at -20oC. After 3-4 weeks of culture the cells were
harvested and analyzed.
T-cell Stimulation.
Peripheral blood lymphocytes (PBL; 1 x 106/well of 24-wells plate) obtained at baseline and
during the trial were cultured in complete RPMI medium supplemented with 5% HAB
(Biowhittaker, Walkersville, MD), recombinant IL-2 (15 U/ml) and IL-7 (25 ng/ml). The cells
were stimulated at a 10:1 ratio with unpulsed DC, DC pulsed with KLH or DC pulsed with
CA9-derived peptides. Also non-stimulated PBL were evaluated. At day 2 half of the medium
was replaced by IL-2 and IL-7 containing medium, at day 5 half of the medium was replaced
by IL-2 containing medium. At days 7-14 PBL were re-stimulated as described above. At day
14 cells were harvested and analyzed. If sufficient DIL were harvested these cells were stimu
lated as described above.
Phenotype Analysis of DC, PBL & DIL
DC were labeled with anti-CD14-FITC (DAKO, Marseille, France) / anti-CD86-PE
(Pharmingen, San Diego, CA), anti-CD80-FITC / anti-CD40-PE (both Immunotech,
Westbrook, ME), anti-CD14-FITC / anti-CD83-PE (Immunotech, Westbrook, ME), anti-MHC
class-I / anti-MHC class-II (both DAKO, Marseille, France). PBL and DIL were labeled with
anti-CD-3-FITC (DAKO, Marseille, France) / anti-CD56-PE (BD Biosciences, Belgium), anti-
CD4-FITC (Immunotech, Westbrook, ME) / anti-CD8-PE (DAKO, Marseille, France). After
centrifugation and washing with PBS the cells were fixed in 1% paraformaldehyde/PBS and
analyzed by FACS analysis (Beckman Coulter, Inc., Fullerton, CA).
Cytokine Profile
Supernatant of the T-cell stimulation assays (PBL and DIL) were collected at days 2 and 9
during the stimulation protocol. The secretion of cytokines into the supernatant was evaluated
using a Bio-Plex Human Cytokine Th1/Th2 Panel (Bio-Rad, Veenendaal, The Netherlands)
which includes antibody-conjugated beads, detection antibody and standards for simultaneous
detection of IL-2, IL-4, IL-5, IL-10, IL-12p70, IL-13, GM-CSF, IFN-gamma and TNF-alpha.
The plates were read on the Luminex 100 apparatus (BioRad)
Detection of CTL specific for CA9MN/G250-derived peptides
Stimulated PBL and DIL were evaluated for the presence of peptide-specific CTL directed
against CA9p254 by DimerX peptide presentation technology (BD Biosciences,
Erembodegem, Belgium), involving passive peptide loading at peptide excess (overnight at
370C, 640x molecular excess) according to the manufacturer's instructions. In brief, PBL were
resuspended in 0.5% BSA/PBS (1x106 cells/50 ml) and polyclonal human IgG was added to
block non-specific binding of the DimerX or antibody reagents to surface Fc receptors.
Peptide-loaded HLA-A2:Ig was added to the sample (2 mg/106 cells), incubated at 4 °C for 1
hour, and washed. Polyclonal human IgG was added (10 minutes room temperature) followed
by the addition of PE-conjugated rat-anti-mouse IgG1 (clone A85-1, Becton-Dickinson,
Alphen aan de Rijn, The Netherlands) and anti-human CD8-FITC (clone 42-8, Becton-
Dickinson) for 30 minutes at room temperature. The cells were washed and analyzed by flow
cytometry.
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Analysis of humoral immune response.
ELISA plates were coated with 2mg KLH (20 mg/ml) or individual CA9 peptides (20µg/well)
overnight at 4oC. Plates were blocked for 2 hours with 1% gelatin/PBS at 25oC. After was-
hing with 0.05% PBS/Tween, plates were incubated with serial dilutions of patient sera obtai-
ned before, during and after treatment, for 1-2 hours at 25oC (starting 1:100, 3-fold dilutions).
After washing, plates were incubated with peroxidase conjugated goat-antihuman Ig (Sigma,
1: 2000) in 1% gelatin/PBS for 30 min at 25oC. Plates were developed with 3,'3,5,'5-tetrame-
thanolbenzidine (TMB) in 0.1 M acetatebuffer pH 5.5/ 0.03% H2O2 for 20 minutes at room
temperature in the dark. Reactions were stopped with 2M H2SO4. Absorbance was measured
at 450 nm.
Immunohistochemical staining of DTH skin biopsies
Cryosections (5µm) of tissue specimen were fixed for 10 minutes in ice-cold acetone. After
washing with PBS the sections were incubated with anti-CD3-Alexa488; anti-CD4-Alexa488,
anti-CD8-Alexa647 (Molecular Probes, Leiden, The Netherlands),  anti-CD8-PE; anti-CD56-
PE; anti-CD4-FITC; or anti-CD11c-PE (Immunotech, Westbrook, ME) for 30 minutes at room
temperature. After repeated washing with PBS, slides were covered with fluorescent mounting
medium (DAKO Cytomatics). Sections were analyzed with a fluorescence microscope or by
confocal microscopy.
Detection of CA9 specific CTL in DTH biopsies was performed as decribed by de Vries et
al.[15]. Briefly, cryosections (8µm) were air- dried and  fixed for three minutes with 4 % para-
formaldehyde and rinsed with PBS. The sections were blocked with 20 % normal goat serum
and incubated with CA9-tetramer (Kindly provided by Dr. R.A. Willemsen, Rotterdam, The
Netherlands) overnight at 4° C in 4% normal goat serum/PBS. After washing with PBS and
fixation in paraformaldehyde for 20 minutes, sections were incubated for 30 minutes with rab-
bit-anti-streptavidine (1:800, Rockland, Gilbertsville, PA) with or without mouse-anti-CD8
(1:100, Pharmingen, San Diego, CA). The specific binding of tetramer was visualized using a
polyclonal goat-anti- rabbit-Alexa 594 (Molecular Probes, The Netherlands) and CD8 was
visualized using a polyclonal goat-anti-mouse- Alexa 488 (Molecular Probes).
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Table 1
Yield of PBMC and DC
 Average  Range 
Yield PBMC x108 24 10 – 50 
Yield DC x 106 282 36 – 792 
% DC / PBMC 13.4 2.6 – 31.7 
 Abbreviations: PBMC= peripheral blood mononuclear cells, DC= dendritic cells, %=percentage
4.4 Results
Patient Characteristics.
Between August 2002 and December 2003, 8 patients with progressive mRCC were included
in the study protocol, according to the inclusion criteria. All patients signed informed consent
approved by the local ethical committee. Patient nr. 1 dropped out because of the development
of pleural effusion and rapid deterioration of the performance status. Patient 6 mentioned visu-
al dysfunction during the visit following the leukapheresis and radiological evaluation revea-
led cerebral metastasis, which led to the withdrawal of this patient from the study protocol.
DC culture.
Sterile, pyrogene free mature DC were obtained for all patients. FACS analysis revealed a typi-
cal mature phenotype of the DC (figure 1). A summary of the amount of PBMC and DC har-
vested and cultured is presented in table 1.
Toxicity.
No significant toxicity (above grade II) due to the DC-based vaccines was observed. Some
patients experienced flu-like symptoms the day of the vaccination, but no additional treatment
or hospitalization was needed. After the second injection local reaction (redness, induration,
pruritis) was observed in most patients for approximately 48 hours following the vaccination.
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        Pt nr 
PBS KLH  CA9p249  CA9p254  DC  DC-KLH  DC-KLH/ 
CA9p249  
DC-KLH/ 
CA9p254  
2 - - - - - +*  (6.5) +*  (9.0) - 
3 - - +*  (4.0)# - - +*  (2.5) +*  (2.5) +*  (3.2) 
4 - - - - +* (<0.3) +* (<0.3) +*  (<0.3) +*  (<0.3) 
5 - - +*  (1.4) - - + +*  (0.6) +*  (2.0) 
7 - - - - - +* (<0.3) +*  (<0.3) +*  (<0.3) 
8 - - +*  (<0.3) - +*  (0.5) +* (1.3) +*  (0.7) +*  (0.6) 
 A week after the 5th vaccination (week 13), patients received 8 injections to evaluate delayed-type-hypersensi-
tyvity reactivity. Patients were injected with PBS, KLH, CA9p254, CA9p249, unpulsed DC, DC pulsed with
KLH and DC pulsed with KLH + CA9p254 and KLH + CA9p249 respectively. A DTH injection site was con-
sidered positive when an induration of > 0.5cm was observed. -: No DTH reaction, +: positive DTH reaction,
*: biopsy of DTH reaction collected, #: numbers between brackets represent outgrowth of DIL x 106, harvested
after 2-3 weeks culture.
Table 2
Delayed-type-hypersensitivity reactivity and - infiltrating lymphocyteoutgrowth
Clinical outcome.
Evaluation of tumor growth by CT-scanning
performed 4 weeks after the 5th vaccination
revealed progressive disease in all 6 patients
receiving the DC vaccination.
Evaluation of humoral responses.
Serum samples taken at baseline and at
week 4, 7, 13 and 17 were analyzed for the
presence of antibodies against KLH or CA9-
peptide. Antibodies against KLH were
absent at baseline. During the trial an incre-
ase of anti-KLH antibodies up to week 17
was observed in all patients (figure 2). No
anti-CA9 peptide specific antibodies were
observed.
Evaluation of cellular immune responses in peripheral blood.
PBL phenotyping showed no change 
in the distribution pattern of CD3+, CD4+, CD8+ and CD56+ cells in time (baseline, week 4,
week 13). The percentage DimerX-positive PBL varied from 0.0% to 0.3%. Analysis of the
secretion of cytokines into the supernatant of the T-cell stimulation assay of PBL showed a gra-
dual increase in Th2 cytokines (Il5 and IL13) from baseline to week 13 in 4/6 patients (figure
3). For the other cytokines and conditions the results were highly variable without any appa-
rent distinguishable pattern.
Delayed-Type Hypersensitivity (DTH).
No measurable DTH reactivity was observed at baseline. In contrast, DTH was observed in
almost all KLH challenges (table 2). Clusters of infiltrating leukocytes were observed in all
biopsies collected, which consisted of CD4+ and CD8+ cells at approximate equal numbers. 
The amount of DTH-infiltrating leukocytes retrieved after 3-4 week culture varied substanti-
ally between biopsies and patients (table 2). Phenotypic analysis of DIL showed virtually
exclusive outgrowth of CD4+ T-cells in the evaluated patients, regardless of which challenge
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Figure 1
FACS analysis of monocyte-derived mature DC
was studied, including unpulsed DC. The data of a representative patient are shown in table 3.
Analysis of cytokines secreted by DIL revealed high cytokine levels of all cytokines examin-
ed in the supernatant of days 2 and day 9. A slight bias toward a Th2 cytokine profile was
observed (results not shown).
In 2 biopsies sufficient DIL were available to perform a cytotoxicity assay. No efficient pepti-
de-specific lysis of HLA-matched, CA9-positive target cells was observed.  
Tetramer staining did not reveal  any tetramer-positive cell in any of the skin biopsies.
4.5 Discussion
Dendritic cell (DC) vaccines have demonstrated the possibility to induce antitumor activity in
RCC patients [9,10,15]. Appropriate DC maturation and activation are essential components
to achieve clinical responses, albeit that only a minority of patients responded even when ade-
quately matured DC were administered. In RCC, vaccination with tumor-lysate pulsed matu-
re DC resulted in clinical responses, and vaccination with mature, autologous DC transfected
with total tumor RNA showed vaccine-induced T cell responses against various antigens,
including CA9 [10,15]. This antigen is expressed in all clear cell RCC, but not in most normal
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KLH-ELISA of sera from a representative patient. The serum of a healthy donor (NHS) was used as negative
control. 
Figure 2
Humoral anti-KLH response 
tissues [11,12]. Considering the restricted tissue distribution, the identification of MHC class
I and MHC class II CA9-derived peptides with the ability to induce CD8 + CTL and CD4 +
DR-restricted Th cells and that vaccination with total tumor RNA loaded DC leads to CA9 spe-
cific responses we hypothesized that CA9-peptide vaccination might lead to induction of CA9
specific CTL and antitumor responses. To investigate whether vaccination with CA9-peptide
loaded DC could induce CA9-specific responses, a clinical trial in patients with progressive
mRCC was performed. As anticipated, and in accordance with comparable clinical trials, no
significant side effects were observed. Unfortunately, no change in the disease-course of the
RCC patients was noted.
One of the main objectives of this clinical trial was to explore whether CA9 peptide-loaded
DC vaccination could induce CA9-specific immune responses. Almost all challenges with pul-
sed DC demonstrated DTH reactivity, whereas peptide challenges showed very little reactivi-
ty: KLH and CA9p254 were negative and in only three cases a positive DTH reaction was
noted against CA9p249. The reactivity against the CA9-peptide pulsed DC may not reflect
CA9-peptide reactivity, but rather KLH-directed reactivity, since all CA9-peptide pulsed DC
were also pulsed with KLH. Because DTH reactivity has not been predictive for a successful
response to vaccination and because we were unable to distinguish between KLH and CA9-
directed DTH reactivity we examined DTH biopsies. A recent study has suggested that DTH
biopsies may be a valuable and reliable source for immunomonitoring purposes [16]. We
investigated skin biopsies of DTH sites by immunohistochemistry and analysed leukocytes
outgrowing from DTH biopsies. Although immunohistochemical analysis of DTH biopsies
revealed CD4+ and CD8+ infiltrating leukocytes, we did not observe outgrowth of CA9-pep-
tide specific cells in any of the biopsies. Outgrowing leukocytes consisted almost exclusively
of CD4+ cells. In line with the CD4+ phenotype, analysis of cytokine production showed a
slight bias towards a Th2 cytokine profile (Il5 and IL13). Since the outgrowing cells could be
a poor representation of the infiltrate due to selection, in situ tetramer staining on the skin biop-
sies was performed. Unfortunately, in situ-tetramer staining also failed to detect CA9-specific
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Following approximately 3 weeks of culture, outgrowing DTH-infiltrating
leukocytes were evaluated by FACS analysis.
Origin b iopsy % CD3 % CD4 % CD8 % CD56 
Normal skin 65 32 0 4 
CA9p249 92 93 2 2 
KLH 88 84 2 8 
DC-KLH/CA9p249 87 87 3 7 
DC-KLH/CA9p254 91 86 1 5 
 
Table 3
Phenotypic analysis of DTH-infiltrating leukocytes of patient 5
T cells. I.e, no specific CA9-related cellular immune response was observed in any of the
DTH. The infiltrating leukocytes observed in the DTH biopsies are most likely the result of
the vast amount of locally produced chemokines by the injected mature DC.
Monitoring of humoral responses revealed anti-KLH IgG responses in all patients, but anti-
CA9 peptide IgG could not be detected. The anti-KLH IgG response is in agreement with other
studies, and confirms the functionality of the DC used. 
The absence of anti-CA9 peptide IgG and T cell responses suggests that these peptides are
poorly immunogenic in vivo despite convincing in vitro evidence demonstrating their capaci-
ty to induce genuine immune responses [13,14]. Alternatively, the complete CA9 protein may
not contain immunogenic peptides. However, vaccination of mRCC patients with RCC tumor
RNA loaded DC lead to a bona-fide expansion of CA9 specific CTL, demonstrating that the
protein does contain immunogenic peptides[16]. Secondly, in a comparable approach, Uemura
et al. immunized progressive, cytokine refractory metastatic RCC patients with HLA-A24
restricted peptides emulsified in Montanide (Uemura, pers. commun.). This vaccination resul-
ted in induction of powerful CA9-specific, HLA-restricted lytic activity against RCC cells in
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Figure 3
Evaluation of cytokine production
Cytokine secretion of PBL cultured in the absence or presense of peptide-loaded DC. A, B: IL5 secretion 2
days (A) or 9 days (B) after stimulation. C, D: IL13 secretion 2 days (C) or 9 days (D) after stimulation.             
=Mean value.  
most patients and rapid and high production of anti-CA9 antibody responses. Moreover, clini-
cal responses were observed. The above clearly suggest the possibility to induce CA9 specific
immune responses. Future studies should focus on other CA9-related peptides or alternative-
ly, focus on immunization with whole CA9 protein, because this would result in presentation
of all possible CA9-peptides, alleviating the need for HLA-matched vaccination. 
As mentioned, new treatment modalities (Bevacizumab, Sutent (SU11248), Sorafenib (BAY
43-9006)) that focus on gene products upregulated as a consequence of mutations in the VHL-
gene show promising results [3-6]. Of interest, there is a clear link between CA9 and VHL. It
will be interesting to combine various treatments: e.g. reduction of VEGF-induced immuno-
suppression by bevacizumab to improve specific anti-tumor immune responses induced by
vaccination strategies. Secondly, the extend of clinical cross-resistance is unknown, which pro-
vides a rational for combination.
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5.1 Abstract
Purpose: Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen
found on >85% of renal cell carcinoma (RCC). A multicenter phase II study was performed to
evaluate the safety and efficacy of WX-G250 in metastatic RCC (mRCC) patients.
Patients & Methods: Thirty-six patients with mRCC were included. WX-G250 was given
weekly by IV infusion for 12 weeks. Patients with stable disease or response were eligible to
receive additional treatment for 8 weeks.
Results: None of the 36 enrolled patients experienced any drug related grade III or IV toxici-
ty. Only 3 patients had grade II toxicity possibly related to the study medication. Ten patients
obtained a stable disease and received extended treatment. One complete response and a sig-
nificant regression was observed during the follow-up of the treatment. Five patients with pro-
gressive disease at study entry were stable for more than 6 months after study entry. The medi-
an survival after treatment start was 15 months.
Conclusion: The weekly schedule of WX-G250 was well tolerated. With a median survival of
15 months after start of this treatment and two late clinical responses, WX-G250 seems to be
able to modulate mRCC. To improve activity of WX-G250 specific antibody dependent cellu-
lar cytotoxicity (ADCC) and the clinical response rate, currently combinations of WX-G250
with cytokines are in phase-II trials.
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5.2 Introduction
Patients with metastasized renal cell carcinoma (mRCC) have a poor prognosis. Up to one
third of the newly diagnosed patients present with metastatic disease and another 33% of the
patients develop recurrent disease after surgery with curative intent [1]. In view of well docu-
mented spontaneous remissions, the immune system appears to play a role in the natural histo-
ry of the disease [2]. Against this background the main focus of treatment of mRCC has been
on immunotherapy. Currently, interferon-alpha (IFN-a) and interleukine-2 (IL-2) are most
commonly used in the treatment of mRCC, either alone or in combination [3,4]. However, the
response rates are low and the toxicity significant. Therefore, new treatment modalities are
being studied [5,6].
Currently, several monoclonal antibodies (mAb) have been approved for the use of cancer tre-
atment, e.g. in non Hodgkin's lymphoma [7]. In RCC, the chimeric monoclonal antibody WX-
G250 has been identified and developed for both diagnostic and therapeutic purposes [8,9]. It
recognizes the Carbonic Anhydrase-IXG250/MN (CA9) antigen expressed in >95% of RCC
of the clear cell type [10]. Moreover, CA9 is not expressed in normal kidney tissue and in other
normal tissues the expression is highly restricted and limited to large bile ducts and gastric epi-
thelium [8]. The observation that WX-G250 was able to mediate antibody dependent cellular
cytotoxicity (ADCC) against several RCC cell lines [11] led to the initiation of the present
study.
5.3 Patient & Methods
Study Design
A phase II, prospective, open-label, single-arm, multicenter study was initiated. Patients with
mRCC received weekly doses of 50 mg WX-G250 for 12 weeks. Study objectives included the
evaluation of efficacy, safety, immunogenicity and biological activity of the WX-G250.
Patients were treated at five medical centers: Johannes-Gutenberg University Hospital Mainz,
Germany (enrolled patients: n=14); Hospital Northwest Frankfurt/Main, Germany (n=11);
University Medical Center Nijmegen, The Netherlands (n=6); Philipps University Hospital,
Marburg, Germany (n=4); and Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The
Netherlands (n=1). All patients signed an informed consent approved by the local ethical com-
mittees of the respective hospitals. Patients were recruited between June 14, 2000 and
December 20, 2000. 
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Patient population:
All patients had primary RCC of clear cell histology and prior nephrectomy. Inclusion criteria
were: bidimensionally measurable disease with lesions < 5 cm in diameter and at least one
lesion of > 1 cm; life expectancy > 28 weeks; Karnofsky Performance status > 70%; serone-
gative for human immuno-deficiency virus (HIV) and hepatitis B surface antigen; absolute
neutrophil count (ANC) 2.0 x 108/dL; platelet count 100 x 108/dL; hemoglobin > 6.5 mmol/
L (equals 10.5 g/dL); total bilirubin < 1.5 x upper limit of normal (ULN); AST, ALT <3 x ULN;
(<5 x ULN if liver metastases present). Patients with clinical signs of CNS metastases and
patients with bone metastases only were excluded.
Antibody:
WX-G250 is a human/mouse chimeric mAb derived from murine mAb G250 by recombinant
DNA techniques. WX-G250 is similar regarding binding affinity and specificity in comparison
with the murine G250 IgG [9]. All clinical lots were generated starting from a cell bank accor-
ding to current GMP requirements. The antibody was supplied by Wilex AG (München,
Germany).
Treatment:
Patients received 50 mg WX-G250 once a week by intravenous infusion for 12 weeks follo-
wed by radiographic evaluation 4 weeks later. Patients with stable disease or a tumor respon-
se were eligible for extended treatment, consisting of 8 additional weekly infusions of WX-
G250. The WX-G250 was dissolved in 10 ml solution for injection, pre-filtered through a low-
protein binding 0.2um filter and infused in 50-100 ml normal saline over a period of 30 minu-
tes. Patients were observed for at least two hours for blood pressure, pulse, temperature and
allergic reactions after completion of the infusion. The 50 mg dose was chosen based on the
following observations: 1) a single dose of 50 mg WX-G250 (radiolabeled with 131Iodine)
was safe in 16 RCC patients [9], 2) 50 mg WX-G250 was sufficient to reach maximum upta-
ke of the antibody in RCC [9] and 3) the results of a multidose phase I study with escalating
WX-G250 doses showed that weekly doses of 25 mg/m2 (corresponding to the 50 mg dose
used in this study) caused no clinical or laboratory drug related adverse events during 6 weeks
treatment [12]. The interval of the application was selected based on the WX-G250 serum half-
life of approximately 70 hours [9]. Therefore it was expected that levels of WX-G250 adequa-
te to induce ADCC would persist for at least one week [11]. Weekly administration was not
expected to lead to significant cumulative increase of serum levels of WX-G250.
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Table 1
Charactistics of the evaluated patients
Pt no. Sex Age Prior tumor therapy (best response) Karnofski 
Clinical 
status at start 
Metastasis Number of infusions 
Response 
after first 
cycle 
Survival 
(months; Until 
January 2002) 
1 M 68 IFN+Vinbl (PD) 90-100% PD Adrenal 12 PD 6 
2 F 45 IFN+Vinbl (PD) 70% PD Lung & liver 4 PD 2 
3 F 75 None 80% PD Lung 12 PD 4 
4 M 51 None 80% PD Lung, liver & LN 11 PD 3 
5 F 77 None 90% PD Lung 5 PD 2 
6* M 66 
IFN+Vinbl (SD) 
IFN+Vinbl (PD) 
5FU+CF (PD) 
80% PD Lung & liver 20 SD 18+ 
7 F 58 Radiation (PD) 90-100% PD Lung 12 PD 18+ 
8 M 77 IFN+Vinbl 5FU+CF 80% PD Lung & bone 4 PD Date unknown 
9* M 68 IFN+Vinbl (SD) 5FU+CF (SD) 90-100% PD Lung, pleura, adrenal 20 SD 18+ 
10 M 69 IL-2/IFN/5FU (SD) IL-2/IFN/5FU red (PD) 90-100% PD Lung & liver 12 PD 18+ 
11 M 66 None 90-100% PD Lung & LN 12 PD 17 
12 F 67 None 90-100% UN Liver, spleen & LN 12 PD 18+ 
13 F 64 IFN+Vinbl (PD) 90-100% PD Lung & liver 11 PD 4 
14 M 72 None 90-100% PD Lung 7 PD 1 
15 M 51 IFN+Vinbl (PD) 90-100% PD Lung, LN, pancreas 12 PD 17+ 
16 M 54 
IFN+Vinbl (PD) 
IFN+cis RA (PD) 
5FU+CF (PD) 
90-100% PD LN, contralateral kidney & psoas muscle 12 SD 17+ 
17 M 67 IFN+Vinbl 80% PD Lung 5 PD 7 
18 M 50 IFN (PD) 90-100% PD Lung 12 PD 9 
19 M 43 None 90-100% PD Lung & LN 12 PD 8 
20 F 60 None 80% UN LN 12 PD 11 
21* M 69 None 90-100% UN lung & LN 20 SD 16+ 
22* M 70 None 90-100% UN LN 20 SD 13 
23* M 61 None 80% PD Lung, LN, & Liver 20 SD 16+ 
24* M 56 IL-2 (SD) DC vaccination (SD) 90-100% PD LN 20 SD
 15+ 
25* F 52 IFN+cis RA (CR) 90-100% PD Other kidney 20 SD 15+ 
26 M 69 IL-2/IFN/5FU (PD) 80% PD Lung & LN 12 PD 15+ 
27* M 57 IL-2/IFN/5FU (PR) 90-100% UN Lung 20 SD 15+ 
28* F 76 None 90-100% PD Lung & adrenal 20 SD 14 
29 M 66 IL-2/IFN/5FU (SD) IL-2 inhalation (PD) 80% PD Lung & LN 12 PD 15+ 
30 F 65 
IL-2/IFN/5FU (PD) 
Toremifene + Vinbl 
(PD) 
90-100% PD Lung & LN 12 PD 14+ 
31 F 70 
IFN+Vinbl (PR) 
IFN+Vinbl (PD) 
IFN+Vinbl (PD) 
90-100% PD Lung 12 PD 14+ 
32 M 76 None 90-100% PD Lung 12 PD 14+ 
33 M 71 None 80% PD LN & Pleura 12 PD 14+ 
34 M 57 Vaccination (PD) 90-100% PD Lung 12 PD 7 
35 M 67 IFN+cis RA (SD) 90-100% PD Lung & LN 10 PD 5 
36* F 73 None 80% PD Lung 20 SD 13+ 
 
*: Patients who received extended treatment.
Abbreviations: Sex: M= male, F= female. Response: PD= progressive disease, SD= stable disease, PR= parti-
al response, CR= complete response, UN= unknown. Metastasis: LN= lymphnode. Prior treatment: IFN=
interferon-alpha, Vinbl= vinblastine, 5FU= 5-fluorouracil, CF=  calcium folinate, IL-2= interleukin-2, cis RA=
cis-retinoic acid, DC= dendritic cell.
HACA evaluation:
A sandwich type ELISA was used to analyze human antibody chimeric antibody (HACA)
levels in  serum of patients as described previously [9]. In brief, unconjugated WX-G250 was
coated onto ELISA plates, followed by incubation with the serum of the patient. Detection of
anti WX-G250 HACA was performed using biotinylated WX-G250, and a streptavidin-bioti-
nylated peroxidase complex. In 22 patients, pretreatment HACA levels were determined.
Blood samples for HACA evaluation were taken before each infusion with WX-G250 and
regularly during follow-up. The serum of a patient with positive HACA levels obtained from
an unrelated WX-G250 trial was used as positive control. The calibration curve for the quan-
tification of anti WX-G250 HACA was generated using the WX-G250 anti-idiotypic antibody
NUH82 [13]. The limit of detection (LOD) of this ELISA was 8.3 ng/ml (NUH82); limit of
quantification (LOQ) was 27 ng/ml.
Biological activity, ADCC:
At baseline and prior to WX-G250 infusion at week 4 and week 12, venous blood samples
were collected in 4 sodium heparin vacutainerTM CPTTM tubes (Becton, Dickinson & compa-
ny, The Netherlands). The tubes were centrifuged (1500g, 30 minutes) at the treatment site and
shipped overnight to the evaluator. Peripheral blood mononuclear cells (PBMC) were collec-
ted and frozen in 50%FCS / 10%DMSO medium and stored at -170 0C until the time of eva-
luation. To confirm the presence and proportion of natural killer (NK) lymphocytes, immun-
ophenotyping was performed. The biological activity of WX-G250 was analyzed by 4-hour
51chromium release assays at different effector to target cell ratios using autologous cryopre-
served PBMC as effector cells. Target cells were SKRC-17pMW1-cl4 (CA9 antigen transfec-
ted RCC cell line) and SKRC-17 (CA9 antigen negative RCC cell line). As controls for lytic
activity of the PBMC, P815 cells were used as target cells in the presence of anti-P815 rabbit
antiserum ("classic"-ADCC). To evaluate non-specific cellular lytic activity, K562 and Daudi
cells were used as additional target cells, in the absence of WX-G250 antibody. The cytolytic
activities were expressed as percentage weighted mean of specific cytolysis (WMSL) [14].
ADCC measured against the target cells incubated with the WX-G250 antibody (1 mg/ml) was
corrected for the ADCC seen against the target cells incubated without the WX-G250 antibo-
dy.
Patient monitoring and efficacy evaluation:
Patients were monitored for safety, biological activity of WX-G250, HACA development and
clinical antitumor effects. At baseline and weeks 4, 12 and 16 medical histories, physical exa-
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minations, urinalysis, and laboratory studies including complete blood count and chemistry
panel were performed. Toxicity was evaluated according to the Common Toxicity Criteria
(Version 2.0, Apr 1999, National Cancer Institute). Computed tomography scans of the thorax
and abdomen were performed at baseline, at week 16 and 4 weeks after the extended treatment,
when applicable. Tumor responses were evaluated according to the following WHO criteria:
Complete response (CR): The disappearance of all known disease determined by two evalua-
tions not less than four weeks apart. Partial response (PR): >50% decrease in the sum of pro-
ducts of largest and perpendicular diameters of the lesions that have been measured to deter-
mine the effect of therapy by two evaluations not less than four weeks apart, in the absence of
new lesions or progression of any lesion. Stable disease (SD): The total tumor size has less
than 50% and the increase is less than 25% in the size of one or more measurable lesions.
Progressing disease (PD): a 25% or more increase in the size of one or more measurable
lesions, or the appearance of new lesions. For the CT and MRI evaluations an independent cen-
tral review was performed as requested by protocol.
Statistical methods:
The study had a two-stage design. In the first stage, 32 evaluable patients with mRCC were
included. Twenty-two additional patients were allowed to participate (54 patients in total) if at
least three objective responses were observed at the time of the radiological evaluation at week
16. The study had to be terminated if less than three patients or more than five had an objecti-
ve response. At the maximum enrollment number of 54 patients the trial was powered at 80%
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Table 2
Adverse events registered during the study, stratified by NCI class and Grade.
NCI class Events (N) Pts (N) Pts (%) n.a. Gr I Gr II Gr III Gr IV 
Pain 32 15 41.7 0 12 13 7 0 
Gastrointestinal 26 14 38.9 0 14 12 0 0 
Pulmonary 20 9 25.0 0 5 5 6 4 
Cardiovasculair (General) 17 12 33.3 0 8 4 5 0 
Constitutional Symtoms 15 9 25.0 0 10 4 1 0 
Neurology 11 8 22.2 0 3 6 2 0 
Blood/ Bone marrow 10 5 13.9 0 1 5 4 0 
Not to classify 7 5 13.9 4 3 0 0 0 
Renal/ Genitourinary 5 4 11.1 0 2 1 2 0 
Hemorrhage 5 3 8.3 0 3 0 1 1 
Hepatic 4 2 5.6 0 0 0 4 0 
Infection/ Febrile Neutropenia 3 3 8.3 1 1 1 0 0 
Metabolic/ Laboratory 3 3 8.3 0 1 1 1 0 
Allergy/ Immunology 1 1 2.8 0 0 1 0 0 
Ocular/ Visual 1 1 2.8 0 0 1 0 0 
Total 160 30 83.3 5 63 54 33 5 
 
Abrevations: Pts= Patients, Gr= Grade, n.a.= Grade not specified.
and based on a < 0.05 to detect a difference between an assumed spontaneous response rate of
5% and an underlying true response rate of 15%.
5.4 Results
Patient characteristics (table 1)
From June 2000 to December 2000 a total of 36 RCC patients were included. The study popu-
lation (mean age 64 years, range: 42-77 years, 12 females and 24 male) displayed a total of
107 target lesions in different sites at study entry. In 29 patients (80.5%) disease progression
was documented before study entry, for 4 patients the status was not rated, the remaining 3
were not progressive. Of the 36 evaluated patients, 20 patients received prior systemic treat-
ment that resulted in one CR, one PR, 3 SD. Fifteen patients did not respond to cytokine tre-
atment.
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Abrevations: NK= natural killer cell, ADCC= antibody dependent cellular cytotoxicity, ND= No data. %NK
cells = percentage NK cells of viable leukocytes. Cytolytic activities expressed as %WMSL at Effector-to-
Target-ratio of 20:1.cG250-ADCC: cG250 mAb induced cytolysis of G250-ligand expressing target cell.
'classic'-ADCC: anti-P815 Ab induced cytolysis of P815 target cell (=positive control). NK-activity: cytoly-
sis of NK-sensitive target cell K562.
Subject Treatment day Immunophenotyping % NK cells 
Cytolytic avtivity 
cG250-ADCC 
Cytolytic avtivity 
“classic” ADCC NK-activity 
#01 0, 21, 76 5, 4, 4 16, 9, 10 40, 29, 27 -, 5, 4 
#06 0, 21, 77 9, 9, 7 14, 14, 11 38, 32, 40 16, 19, - 
#07 0, 21, 77 9, 11, 9 8, 16, 5 94, 100, 50 -, 35, - 
#09 0, 28, 77 7, 8, 11 1, 1, 2 45, 72, 49 -, 24, 28 
#10 0, 21, 77 6, 5, 2 0, 1, 0 40, 32, 38 -, -, - 
#11 0, 21, 77 8, 8, 5 10, 7, 5 55, 42, 48 -, -, - 
#12 0, 21, 77 ND 3, 3, 2 32, 39, 36 -, -, - 
#13 0, 21, 78 ND 2, 2, 2 27, 27, 22 -, -, - 
#15 0, 21, 77 ND 3, 1, 1 20, 16, 21 -, -, - 
#16 0, 21, 78 14, 13, 10 14, 25, 26 37, 47, 50 4, 8, 6 
#18 0, 29, 85 1, 1, 1 0, 2, 0 49, 37, 15 0, 1, 0 
#19 0, 21, 77 6, 2, 1 1, 0, 0 34, 38, 9 0, 0, 0 
#20 0, 21, 77 1, 1, 2 1, 2, 3 2, 6, 8 0, 2, 1 
#21 0, 21, 77 12, 12, 7 4, 4, 3 25, 23, 17 5, 5, 3 
#22 -7, 21, 77 7, 4, 5 15, 7, -  31, 40, - 29, 16, - 
#24 -8, 21, 77 9, 4, 4 6, 5, 5 55, 36, 41 17, 16, 45 
#25 0, 21, 77 7, 7, 5 14, 15, 18 32, 37, 36 24, 23, 38 
#26 0, 50, 78 6, 4, 13 0, 0, 3 16, 20, 40 3, 6, 20 
#27 0, 21, 77 5, 4, 5 7, 9, 11 44, 32, 32 -, -, - 
#28 0, 28, 84 2, 3, 3 0, 0, 0 24, 22, 19 4, 4, 4 
#29 0, 28, 78 1, 1, 2 0, 1, 2 9, 8, 17 0, 0, 1 
 
Table 3
Immunophenotyping of ADCC
Safety evaluation (table 2)
All 36 patients received at least one dose of WX-G250, and were assessed for safety. No dose
reduction was necessary. Of the recruited 36 patients, 30 experienced a total of 160 adverse
events during the course of the study. All grade 3 and 4 toxicities were considered not to be
related to the study medication. An overview of the observed toxicities is given in table 2. The
grade 4 toxicities consisted of dyspnea and pulmonary insufficiency (patient 4), dyspnea at rest
(3), respiratory insufficiency (5) and gastrointestinal bleeding (13). Two patients (4, 5) died
during the study (defined as death within 30 days after the last application of study medica-
tion), both due to progression of their disease. None of the serious adverse events (including
the deaths) were related to study medication, but due to underlying disease.
Evaluation of HACA:
In the evaluated pre-treatment sera of 22 patients, no HACA levels were detected. In three
samples of two patients (18, 27) levels higher than the LOD could reproducibly be detected.
Serum of patient 18 showed an equivalent of 76 ng/ml anti-G250 antibody NUH82 at treat-
ment week 12. In sera of patient 27 an equivalent of 49 ng/ml anti-G250 antibody NUH82 at
extension week 1, and a value between the LOD and LOQ at extension week 8 could be detec-
ted.
Immunological monitoring (table 3):
Of eighteen patients phenotypic analysis of PBMC was performed (table 3). Consecutive
samples of every patient were tested simultaneously to exclude assay-to-assay variation. In 15
of these 18 patients the percentage of NK cells was >2% of leukocytes in at least one of the
samples (range: 1% to 14%). The percentage NK cells in individual patients remained rather
constant during treatment. Consecutive samples of twenty-one patients were tested for ADCC
capacity (table 3). Nine out of 21 patients showed moderate (5-25%) to high (>25%) levels of
WX-G250-ADCC activity. Five out of 21 patients showed low levels of WX-G250-ADCC and
7 out of 21 patients showed no WX-G250-ADCC activity. Nineteen of 21 patients tested sho-
wed normal levels of "classic"-ADCC activity. In general, WX-G250 related ADCC remained
unchanged during the treatment.
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Clinical response (table 1):
Clinical progression before week 16 was seen in 8 patients. In 4 of these patients progression
occurred within 6 weeks after study entry and for those patients an additional patient was
included, in accordance with the protocol. Patient 16 was judged as SD according to an outsi-
de radiologist, but was subsequently lost to follow-up. Independent central tumor assessment
was performed at week 16 in the remaining 27 patients. Radiographically proven progression
of the disease was observed in seventeen patients, who therefore did not qualify for extended
treatment with WX-G250. Ten patients showed stable disease after 12 weeks of treatment and
continued treatment consisting of eight additional weekly infusions of WX-G250. The clinical
status of these patients was assessed in week 24 and eight out of ten patients still showed sta-
ble disease. After the end of extension treatment the patients were routinely followed at three
monthly intervals. The follow-up evaluation revealed a minor response in patient 9 in week 44
and a complete response in patient 21 in week 38. Evaluation of survival showed a median
time to death of 15 months after the start of the WX-G250 treatment. The evaluation of the first
stage of the study did not show 3 objective responses at the time of radiological evaluation at
week 16. Consequently, the study did not enter the second stage of the trial.
5.5 Discussion
We performed a phase II, prospective, open-label, single-arm, multicenter study in patients
with advanced RCC receiving weekly doses of 50mg WX-G250 for 12 weeks to evaluate the
potential therapeutic effect of WX-G250. WX-G250 recognizes the antigen CA9 that is homo-
geneously expressed in virtually all clear cell RCC. More importantly, expression in normal
tissue is extremely limited, making this antigen an attractive target for immunotherapy.
During the trial no serious drug related clinical or laboratory adverse events were observed,
and no dose adjustment was necessary. Therefore the toxicity profile of WX-G250 is favora-
ble and comparable with prior studies evaluating WX-G250 [9]. WX-G250 is a murine-human
chimeric antibody; and may consequently induce the development of HACA. In the current
trial low levels of HACA were detected in only two out of 35 patients (8 and 27). The HACA
levels were not associated with clinical symptoms, which is in accordance with earlier studies
evaluating WX-G250 [9]. This study demonstrates that multiple infusions with WX-G250 are
well tolerated and can be given safely.
Evaluation of the first stage of the trial showed less than 3 objective responses needed to con-
tinue into the second stage of the trial and thus the trial was terminated. Nevertheless, follow-
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up revealed two objective responses: Patient 9 presented at study entry with multiple progres-
sive metastases. After both the first course and extended treatment, the lesions were rated as
stable. In the following months, radiological evaluation showed a decrease of the target
lesions. Taking all measurable lesions into account, the response remained slightly below the
50% decrease required for a partial remission, making it a minor response. Patient 21 started
treatment with WX-G250 immediately after nephrectomy. At study entry he presented with
lymph node metastases and multiple pulmonary lesions. The size of the lesions decreased 29%
between week 16 and week 24, and was therefore rated as stable disease. In week 38 after
study start a complete remission of all the lesions was documented. Since spontaneous remis-
sions of RCC metastases after removal of the primary tumor do occur [2], we cannot exclude
that the clinical observation of patient 21 was a reflection of the natural history of the disease,
unrelated to WX-G250. 
Eleven patients were rated with stable disease at the radiological evaluation at week 16. Of
those patients, 8 showed progressive disease at study entry, of which 2 patients (6, 23) with
previously progressive liver lesions and others after progression under previous immunothera-
py regimens. These are events that rarely occur, even after "standard" cytokine treatment [15-
17]. Collectively, these results suggest that WX-G250 has the capacity of modulating the natu-
ral history of metastasized RCC with a safe toxicity profile.
ADCC is suggested to be the main effector mechanism of WX-G250 [11] and is mediated by
the interaction between the Fc-region of an antibody bound to a tumor cell and the Fcg recep-
tors on immune effector cells, such as neutrophils, macrophages and natural killer (NK) cells
[18]. In our trial, the levels of WX-G250 mediated ADCC differed between the patients: 42%
of the patients showed moderate ADCC, whereas 33% showed no ADCC at all. There was no
clear correlation between the proportion of NK-cells and the level of WX-G250 mediated
ADCC and no correlation between the in-vitro levels cytotoxicity and the clinical responses.
This high variability in observed ADCC capacity and number of NK-cells was also found in
healthy donors (personal observations), suggesting that the observed variation was not the
result of the disease status of the patients. Molecular studies have shown significant polymor-
phism in the genes for the different Fc receptors [19]. These polymorphisms may have impor-
tant functional consequences. The pattern of Fc gamma RIIIA expression polymorphism is
probably correlated with the ability of NK cells to perform ADCC. This may be the reason that
no correlation between the proportion of NK-cells and level of WX-G250 mediated ADCC
was observed.
In summary, the weekly schedule of intravenous WX-G250 in patients with mRCC was safe
and well tolerated. Evaluation of the immunogenecity of WX-G250 demonstrated that an
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increased level of HACA does not lead to clinical symptoms. In our trial, 1 complete respon-
der, one minor response and a substantial number of durable disease stabilizations were obser-
ved with WX-G250 monotherapy. The median survival after study entry was 15 months. This
suggests the capacity of WX-G250 to modulate the natural history of metastatic RCC.
Recently was shown that a variety of cytokines e.g. interleukin-2 and interferon-gamma, led
to up-regulation of WX-G250 mediated ADCC [20]. Subsequently, phase-II trials optimizing
treatment schedules with WX-G250 by combination with cytokines have been initiated.
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CHAPTER 6
A CLINICAL TRIAL WITH CHIMERIC MONOCLONAL ANTIBODY
WX-G250 AND LOW-DOSE INTERLEUKIN-2 PULSING SCHEME
FOR ADVANCED RENAL CELL CARCINOMA PATIENTS.
Published: J Urol. 2006 Jan; 175:57-62.
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6.1 Abstract
Purpose: WX-G250 is a chimeric monoclonal antibody that binds to Carbonic Anhydrase-
IXG250/MN, present on >95% of renal cell carcinoma (RCC) of the clear cell subtype. The
suggested working mechanism of WX-G250 is by antibody dependent cellular cytotoxicity
(ADCC). Because the number of activated ADCC-effector cells can be increased by a low-
dose interleukin-2 pulsing schedule (LD-IL-2), a multicenter study was initiated to investiga-
te whether WX-G250 combined with LD-IL-2 can lead to improved clinical outcome of
patients with progressive RCC.
Patients and Methods: 35 progressive RCC patients with clear cell RCC received weekly infu-
sions of WX-G250 for 11 weeks combined with a daily LD-IL-2 regimen. Patients were moni-
tored longitudinally for ADCC capacity. Radiological assessment of the metastatic lesions was
performed at week 16 and regularly until disease progression. 
Results: A durable clinical benefit was achieved in 8 of 35 patients (23%; 3xPR, 5x stabiliza-
tion >24 weeks) and mean survival was 22 months. In general the treatment was well tolera-
ted with little toxicity. The number of effector cells increased during treatment, but the lytic
capacity per cell did not increase. ADCC levels and clinical outcome did not appear to corre-
late.
Conclusions: WX-G250 in combination with LD-IL-2 in patients with mRCC is safe and well
tolerated. With a substantial clinical benefit and a median survival of 22 months in mRCC
patients with progressive disease at study entry the combination therapy showed an increased
overall survival compared to WX-G250 monotherapy and the survival was at least similar to
currently used cytokine regimens, but with a favorable toxicity profile.
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6.2 Introduction
The current prognosis of patients with metastasized renal cell carcinoma (mRCC) is poor [1].
Once metastasized, the disease is difficult to treat since mRCC is unresponsive to conventio-
nal treatment, and, although non-specific immunotherapy has convincingly shown its ability
to induce long-term clinical responses in a subset of patients [2], the overall response rate is
low and side-effects are significant [3]. Consequently, the main focus for new treatments in
mRCC concerns antiangiogenic therapy (e.g. SU11248, BAY- 43-9006 (BAY), and bevacizu-
mab [4-6]) as well as immunotherapeutic modalities with more specificity against RCC and
less side effects [3]. Currently, several monoclonal antibodies (mAb) have become standard
treatment for selected malignancies, with remarkable clinical results and a very favorable toxi-
city profile [7,8]. In RCC, the antibody WX-G250 has been identified [9,10]. It recognizes the
Carbonic Anhydrase-IXG250/MN (CA9) antigen that is expressed in >95% of RCC of the
clear cell type [11]. Moreover, no expression can be detected in most normal tissues, including
the normal kidney [9]. Clinical studies with radiolabeled WX-G250 have revealed excellent
targeting to tumor lesions, corroborating the CA9 antigen expression pattern in metastatic
lesions and potential use of WX-G250 as therapeutic modality [12]. Monotherapy with WX-
G250 in 36 patients with mRCC demonstrated one objective responder, one minor response,
and a median survival of 16 months, suggesting that WX-G250 might have anti-tumor activi-
ty [13]. In-vitro studies have demonstrated that WX-G250 can elicit antibody dependent cel-
lular cytotoxicity (ADCC) [14] which can be upregulated by IL-2 [15,16].  We hypothesized
that WX-G250 combined with a single daily subcutaneous injection low dose IL-2 (LD-IL-2)
could evolve to a new treatment for mRCC.
6.3 Patients and Methods
Study Design & Patient population: 
A prospective, open-label, single-arm, multicenter study was initiated. All patients had clear
cell mRCC with objective progression at study enrollment according the WHO criteria and
prior nephrectomy. Eligible patients had bidimensionally measurable disease with lesions bet-
ween 1 and 5 cm in diameter and a Karnofsky Performance status >80%. Patients with clini-
cal signs of CNS metastases and patients with bone metastases only were excluded. 
Study objectives included the evaluation of safety, induction of human-antibody-chimeric-
antibody (HACA), biological activity (ADCC) and the clinical efficacy of WX-G250 in com-
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bination with recombinant human IL-2 (rHu-IL-2; ProleukinR; aldesleukin; Chiron
Corporation, Emeryville, CA, USA). Patients were treated at Johannes-Gutenberg University
Hospital Mainz, Germany and University Medical Center Nijmegen, The Netherlands. All
patients signed an informed consent approved by the local ethical committees of the respecti-
ve hospitals.
The study had a two-stage design. The first 15 patients received WX-G250 and IL-2 according
to protocol. If at least 1 objective response (PR or CR) occurred, 15 additional patients were
enrolled. Additional patients were included for patients who did not complete the first 6 weeks
of treatment.
WX-G250 is a human/mouse chimeric mAb derived from murine mAb G250 by recombinant
DNA techniques. All clinical lots were generated starting from a chimeric cell bank according
to current GMP requirements. Wilex AG (Munich, Germany) supplied the antibody.
Treatment schedule:
In the first week, IL-2 was administered without WX-G250, to separately observe potential IL-
2 side effects. When IL-2 toxicity was judged acceptable, patients received a fixed dose of 20
mg WX-G250 once a week by intravenous infusion for 11 consecutive weeks. Patients recei-
ved or self-administered the LD-IL-2 for 12 consecutive weeks (Table 1). Patients received 1.8
MIU/day with exception of days 1-3 of weeks 3,5,7,9,11 where 5.4 MIU/day was administe-
red (IL-2-pulsing). 
Patients with disease stabilization or tumor shrinkage at week 16 were eligible for extended
treatment, consisting of 6 additional infusions of WX-G250 in combination with LD-IL-2 tre-
atment.
HACA evaluation:
A sandwich type ELISA was used to analyze HACA levels in the sera of 28 patients as descri-
bed previously [10]. WX-G250 was coated onto ELISA plates, followed by incubation with
the serum of the patient. Detection of anti WX-G250 HACA was performed using biotinyla-
ted WX-G250, and a streptavidin-biotinylated peroxidase complex. Wilex performed all
HACA evaluations.
Biological activity, ADCC:
At baseline and prior to WX-G250 infusion at week 2, 6, 10, 12 and week 16, venous blood
samples were collected and shipped to the evaluator. Peripheral blood mononuclear cells
(PBMC) were collected, frozen in RPMI 1640/ 10%DMSO/ 25% Fetal Calf Serum and stored 
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at -700C. Samples of individual patients were analyzed simultaneously to prevent inter-assay
variation.
The cells were thawed and immunophenotyped by flow cytometric analysis (EPICS XL,
Beckman-Coulter), for CD3, CD14, CD16, CD45, and CD56. CD56dim and CD56bright cell
subpopulations were identified through visual interpretation of the flow cytometric analysis. 
ADCC was analyzed by 51chromium release assays as described previously [13]. Cells were
cultured overnight in RPMI 1640/10% Human AB serum, diluted to effector:target ratios of
80, 40, 20, and 10: 1 respectively and WX-G250 were added (1 µg/ml). Target cells (SK-RC-
52 (CA9pos), SK-RC-17cl4 (CA9pos, transfectant cell line), SK-RC-17cl1 (CA9neg), K562,
Daudi) were harvested and labeled with 51Cr for 60 - 90 minutes. Cells were washed and
added to PBMC/ WX-G250 and incubated at 37°C for 4-5 hours. Released 51Cr was counted
in a liquid scintillation counter (Wallac/LKB). Assays were performed in triplicate.
Spontaneous and maximum release was determined by omission of effector cells and addition
of 2% Triton X-100 respectively. Specific 51Cr release was calculated as:
Cpm 51Cr released - Cpm spontaneous 51Cr released x 100%
Cpm 51Cr maximum released - Cpm spontaneous 51Cr released
Lytic units (LU) were calculated by linear regression analysis for the E:T ratio at which 20%
specific lysis was obtained and expressed as LU/ 10E7 effector cells.
Patient monitoring and efficacy evaluation:
At baseline and weeks 2, 6, 10, 12 and 16 medical histories, physical examinations, urinaly-
sis, and laboratory studies including complete blood count and chemistry panel were perfor-
med. Toxicity was evaluated according to the Common Toxicity Criteria (Version 2.0, Apr
1999, National Cancer Institute). CT of the thorax and abdomen were performed at baseline,
week 16 and 4 weeks after the extended treatment, and at subsequent visits when applicable.
Tumor responses were evaluated according to WHO criteria. CT and MRI evaluations were
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Abbreviations: mg= milligrams; MIU= million international units; i.v.= intravenous’; s.c.=subvutaneous;
IL-2= interleukin-2.
 WX-G250 weekly i.v. IL-2 daily s.c. 
Week 1 None  Day 1-7: 1.8 MIU (low dose) 
Week 2, 4, 6, 8, 10, 12 20 mg  Day 1-7: 1.8 MIU 
Week 3, 5, 7, 9, 11 20 mg  Day 1-3: 5.4 MIU (pulse) 
Day 4-7: 1.8 MIU  
 
Table 1
Treatment schedule
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Pt 
nr 
Age (Sex) Prior tumor therapy (Best response) 
Lag between 
tumornephrectomy 
and study entry 
Number of 
metastatic lesions 
(location)  
Clinical response 
at 16 / 22 weeks 
Survival in 
weeks 
1  55 (m) IL-2/IFN/5FU (SD); 
 IFN/Vinbl/5FU (PD) > 1 year 2 (lung, LN) SD / SD  104+ 
2  49 (m) None  > 1 year 1 (lung) SD / SD  156+ 
3  73 (m) None  < 1 year 1 (LN) PD / NA  35+ § 
4  58 (m) None  < 1 year 1 (lung) PD / NA  133+ 
5  55 (m) Vaccination (PD) < 1 year 2 (lung, LN) SD / SD  105+ 
6  49 (m) None  > 1 year 1 (lung) PD / NA  33 § 
7  51 (m) None  > 1 year 2 (LN, kidney) PD / NA 116 
8  43 (m) IFN-Vinbl (PD) > 1 year 1 (lung) PD / NA 116+ 
9  69 (m) None  < 1 year 2 (lung, LN) PR / PR 116+ 
10  64 (m) None  < 1 year 2 (lung, LN) Early PD / NA 9 § 
11  49 (f) None  < 1 year 2 (lung, LN) PD / NA 18 § 
12  57 (m) None  < 1 year 1 (LN) Early PD / NA 13 § 
13  52 (m) None  > 1 year 2 (lung, LN) PD / NA 141+ 
14  47 (f)  None  > 1 year 1 (lung) Early PD / NA 35 § 
15  67 (m) IFN + IL-2 (PD) < 1 year 2 (lung, LN) PD / NA 44 
16  57 (f) None  > 1 year 2 (lung, liver) Early PD / NA 73 § 
17  74 (f) None  < 1 year 1 (lung) SD / SD 115+ 
18  62 (m) None  > 1 year 2 (LN, kidney) Early PD / NA 5 § 
19  36 (m) None  < 1 year 2 (lung, LN) PD / NA 69 
20  70 (m) None  < 1 year 1 (LN) PD / NA 24 
21  71 (f) None  > 1 year 4 (lung, LN, liver, kidney)  SD / SD 59 § 
22  68 (f) None  > 1 year 2 (lung, LN) PD / NA 114+ 
23  62 (m) IFN + Cis-Retinoid (SD) > 1 year 1 (lung) SD / SD 89 
24  59 (m) None  > 1 year 2 (lung, kidney)  PD / NA 49 § 
26  59 (f) None  > 1 year 2 (LN) PD / NA 99+ 
27  64 (m) None  < 1 year 2 (lung, LN) Early PD / NA 90+ 
28 60 (m) IFN + Cis-Retinoid (SD) > 1 year 2 (lung, LN) SD / PD  55 § 
29  61 (m) None  > 1 year 3 (lung, LN, liver) PD / NA 54+ 
30  70 (m) IFN, IL-2, 5FU (SD) > 1 year 2 (lung, LN) SD / SD 111+ 
31  75 (m) None  > 1 year 2 (lung, adrenal) PD / NA 96 
32  60 (m) None  < 1 year 3 (lung, kidney, 
adrenal)  SD / PD 40+ 
33  47 (m) IFN, IL-2, 5FU (SD) > 1 year 1 (lung)  SD / PD 55 § 
34  61 (m) None  > 1 year 3 (lung, LN, 
adrenal)  PD / NA 105+ 
35  68 (m) None  < 1 year 1 (LN) SD / PD 83+ 
36  61 (f) IFN (PD) > 1 year 2 (lung, kidney) PD / NA 100+ 
 
Table 2
Characteristics of evaluated patients
The characteristics of the evaluated patients.
Abbreviations: m=male, f=female, IL-2= Interleukin-2, IFN= Interferon-alpha, 5FU= 5-fluorouracil, Vinbl=
Vinblastin, SD= Stable disease, PD= Progressive disease, PR= Partial response, LN= lymphnode, NA= not
applicable, + = follow-up ongoing, § = patient deceased.
performed by independent central review.
6.4 Results
Patient characteristics:
Thirty-Six patients with objective progressive mRCC and a Karnofski Performance Status of
> 90% were included in this study. Patient 25 was removed from the protocol because after
pathology revision the primary tumor was diagnosed as non-clear cell RCC. In 5 patients (12;
14; 16; 18; 27) progression occurred within 6 weeks after study entry and for those patients an
additional patient was included, in accordance with the protocol. Characteristics of evaluated
patients are given in table 2.
Safety evaluation:
Thirty-five patients received at least 1 infusion of WX-G250, and were assessed for safety. A
detailed description of adverse events and severity is shown in table 3. No dose reduction was
necessary for WX-G250. During the course of the study, the 35 treated patients experienced a
total of 424 adverse events. Patient 18 died within 30 days after the last application of the study
medication due to rapid progression of the disease. Four more serious adverse events (SAEs)
were observed (pts 10, 12, 14, 16). Three SAE were clearly related to disease progression (pts
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Table 3
Adverse events registered during the study, stratified by NCI class and Grade.
NCI class Events (N) Pts (N) Pts (%) n.a. (N) Gr I Gr II Gr III Gr IV 
Constitutional Symptoms 225 32 91.4 2 170 50 3 0 
Gastrointestinal 88 27 77.1 0 77 11 0 0 
Pain 36 18 51.4 0 25 7 4 0 
Pulmonary 19 12 34.3 0 12 4 3 0 
Dermatology / Skin 12 9 25.7 0 8 4 0 0 
Blood/ Bone marrow 10 5 14.3 0 3 3 4 0 
Hepatic 9 1 2.9 0 1 5 3 0 
Neurology 7 7 20.0 0 6 1 0 0 
Lymphatics 4 4 11.4 1 3 0 0 0 
Cardiovasculair (General) 4 3 8.6 0 3 1 0 0 
Not to classify 2 2 5.7 0 2 0 0 0 
Renal/ Genitourinary 2 2 5.7 0 0 1 0 1 
Cardiovasculair (Arrhythmia) 1 1 2.9 0 0 1 0 0 
Hemorrhage 1 1 2.9 0 1 0 0 0 
Infection/ Febrile Neutropenia 1 1 2.9 0 1 0 0 0 
Metabolic/ Laboratory 1 1 2.9 0 0 0 0 1 
Endocrine 1 1 2.9 0 0 1 0 0 
Total 423 35 100.0 3 312 89 17 2 
 
Abbreviations: N=number, %=percentage, Pts= Patients, Gr= Grade, n.a.= Grade not specified.
10, 12, 14). The SAE of patient 16 was considered to be probably IL-2 related. 
Evaluation of HACA:
HACA levels above the limit of quantification were measured in sera of 2 out of 28 tested
patients (7.1%). The maximum HACA level (± 350 ng/ml) of one patient was reached at the
end of the 1st course of the treatment (week 12) and remained above limit of detection during
follow-up, whereas in the serum of another patient low HACA levels (± 50 ng/ml) only beca-
me detectable in week 16 and were again undetectable in week 26. One patient had HACA-
levels above limit of detection but below limit of quantification (3.6%) and 25 patients
(89.3%) did not develop any detectable HACA at all.
Phenotypic analysis and ADCC of PBMC:
Twenty-eight patients were analyzed. In 50% (14/28) of the patients the absolute blood count
number increased more than twofold after treatment initiation. Phenotypic analysis showed
that within the total population of leucocytes, the percentage of CD3+ (T-cells) remained con-
stant during the study period, whereas the percentage of CD56+ (Natural Killer (NK)-cells)
increased more than a two-fold in 61% (17/28) of the patients. In almost all patients a sharp
increase in the CD56bright cell subpopulation was observed and generally CD56bright levels
declined to baseline levels after IL-2 discontinuation (fig. 1).
Comparison of LU at baseline, week 10/12 and week 16 for WX-G250-mediated-ADCC and
NK-cell-mediated cytotoxicity did not show a significant increase in WX-G250-mediated-
ADCC on cell-to-cell basis (fig. 2a). However, since the absolute blood count number increa-
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Phenotypic analysis of peripheral blood mononuclear cells by FACS. The CD56+bright population (quadrant
4) was visually estimated. Note the increase of the CD56+bright population during IL-2 treatment and subse-
quent normalization.
 
 
Week 2 
 
Week 12 
 
Week 16 
Figure 1
Representative FACS analysis of peripheral blood mononuclear cell phenotyping
sed in many patients the total lytic capacity of these patients increased. A significant higher
lytic capacity against K562; an NK-sensitive cell-line was observed (baseline/week 16:
p=0.004, fig. 2).
No correlation between the percentages of CD3+/16+56+brightcells, the percentages of
CD3+/16+56+dim cells, or lytic activity was observed. No relation between disease outcome
and ADCC and/or NK activity was observed.
Clinical response and survival:
All patients who received at least one dose of WX-G250 (N=35) were included in the effica-
cy analysis. The median survival was 22 months (fig 3). Clinical progression was seen in 6
patients before week 16. In 5 of these patients (12; 14; 16; 18; 27) progression occurred within
6 weeks after study entry and for those patients an additional patient was included, in accor-
dance with the protocol. One patient (#10) died before week 16, leaving 29 patients for inde-
pendent radiological evaluation at week 16 revealing 17 PD, 11 SD and 1 PR (Table 2).
Subsequently, 12 patients continued treatment. Independent assessment of the clinical status of
these 12 patients 4 weeks after the last WX-G250 infusion showed 1x PR and 7x SD. These
patients were routinely followed-up by regular CT-scans showing a second partial responder
at week 37. Patients receiving prior immunotherapy did not show a different response/survi-
val pattern.
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Figure 2
Comparison of Lytic Units measured at baseline, week 10/12 and week 16
igure 3: A representative FACS analysis of CD3/CD56/CD16 phenotyping. Fig. 2a: ADCC, Total Lytic Units  
(SKRC-52 cells) 
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P = 0.111 
P = 0.180 
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Fig. 2b: Natural Killer Cells, Total Lytic Units 
(K562 cells) 
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Pooled data of the patients in which Lytic Units were measured at baseline, week 10/12 and week 16. The
box-plot shows the 25 and 75 percentiles and the standard deviation. The middle of the box represents the
mean. The black dots represents the range. ADCC= Antibody Dependent Cellular Cytotoxicity. SKRC-52 is
a CA-IXpos cell-line. K562 is an NK-sensitive cell-line.
6.5 Discussion
We performed a study with WX-G250 and IL-2 for patients with progressive mRCC of the
clear cell subtype. Although the primary trial objective (objective response =15%) was not rea-
ched, two partial responses were observed (objective response rate 5.7%) and six additional
patients showed stabilization of the disease > 24 weeks. Commonly, SD >24 weeks is recog-
nized as clinical benefit for patients with mRCC with objective progression at entry of treat-
ment. I.e., a clinical benefit was achieved for 23% of our patients. Mean survival was 24
months, which compares favorably with WX-G250 monotherapy, which showed a median sur-
vival of 16 months [13], suggestive of an additive/synergistic effect. Clearly, a randomized
trial would be necessary to be able to compare both treatments. 
Cytokine-based therapies for mRCC lead to a clear survival benefit for responding patients;
overall response rate is approximately 15%, with 5% of the patients showing complete respon-
ses [2]. Unfortunately, the toxicity profile of these cytokine regimens is significant. The over-
all survival of the combination treatment we studied in this
trial appears to be at least equal to the cytokine-based
immunotherapy, but without the unfavorable toxicity pro-
file. 
The side effects of WX-G250/IL-2 were related to the IL-
2 treatment and not to WX-G250: more side effects were
encountered during the pulsing days of the LD-IL-2 regi-
men. WX-G250 monotherapy for patients with mRCC
already showed that WX-G250 had a favorable toxicity
profile [13].
In 3 patients HACA was detected, albeit that the levels
were low (maximum of 350 µg/ml). This low level is in
accordance with earlier trials with WX-G250 [10,13], and
may be insignificant. Indeed, retreatment of the patient
with the highest HACA level did not lead to any adverse
effect. WX-G250 appears to be immunological silent in
the majority of patients when administered weekly. 
We used a LD-IL-2 scheme shown to effect in-vivo expan-
sion and activation of NK-cells [16]. Indeed, the total
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Figure 3:
Overall survival of patients treated with
WX-G250 monotherapy and WX-G250
plus IL-2
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blood count of PBMC increased more than a two-fold in 50% of the patients. The relative
amount of T-cells (CD3+) did not change during the study period, whereas the percentage of
NK-cells (CD3-/56+) did increase in most of the patients. Especially the CD56+bright NK-
subset showed an impressive increase. This increase of activated ADCC effector cells was not
observed in earlier trials with the unconjugated WX-G250 as monotherapy [13] showing that
the IL-2 regimen caused the anticipated effect.
In-vitro studies showed that WX-G250 specific ADCC could be up-regulated with low doses
of IL-2 [14,15]. Nevertheless, ADCC expressed as LU per 107 cells, showed no significant
increase. Cytotoxic activity against the NK-sensitive cell-line K562 increased significantly
between baseline and week 10/12 and week 16. I.e., the potency of the individual effector cells
did not increase, but patients experiencing a significant raise in NK cells developed a higher
lytic capacity. Although we hypothesized that the effector mechanism of WX-G250 might be
ADCC related, no correlation between ADCC levels and the clinical outcome of the study
population was observed. The increase in the total lytic capacity together with the observed cli-
nical results still suggests a role for ADCC in tumor cell kill despite our failure to correlate cli-
nical outcome and ADCC. Possibly, the 4-hour 51Cr release assay does not reflect in-vivo
RCC cell-kill.
It is possible, but unlikely, that the favorable clinical results were the outcome of the LD-IL-2
regimen. Clinical efficacy for low-dose IL-2 treatment has been described at IL-2 doses that
were at least 6-fold higher than the dose of IL-2 used in the current trial [17,18]. Because the
previous trial with WX-G250 already showed a clinical benefit, we consider it more likely that
the LD-IL-2 regimen and WX-G250 act in a synergic fashion. 
Several antiangiogenic therapies are being explored for the treatment of mRCC. Treatment
with bevacizumab (anti-VEGF, 10mg/kg/2 weeks)[6] resulted in significantly longer progres-
sion-free survival (median: 4.8 months) than in the placebo group (median: 2.5 months),
ensuing in closure of accrual on the basis of these differences, despite an overall response rate
of approximately 10%, and no difference in survival between the three study-arms. The results
of SU11248 as second-line therapy for patients with mRCC were reported recently [4].
SU11248 is an oral multi-targeted tyrosine kinase inhibitor of the PDGF-receptor and the
VEGF-receptor. An impressive PR of 40%, time to progression of 8.3 months and median sur-
vival of 16 months were observed, and validation of efficacy is commencing. BAY [5], is ano-
ther oral multi-targeted tyrosine kinase inhibitor, inhibiting Raf kinase and the VEGF-recep-
tor. In a phase III, double-blind trial BAY significantly prolonged progression-free survival
compared with placebo in patients with previously treated mRCC. The activity of BAY appe-
ars to be similar to WX-G250, whereas SU11248 appears to be more potent. However, becau-
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se different endpoints were defined, it is difficult to compare the relative merit of WX-G250,
bevacizumab, BAY, and SU11248.
In conclusion, combination therapy of WX-G250 and LD-IL-2 appears to result in a clinical
benefit for progressive mRCC patients. Together with a median survival of 22 months this
combination is superior to WX-G250 monotherapy and is at least comparable with current
non-specific cytokine regimens for patients with advanced mRCC.
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CHAPTER 7
SUMMARY & FUTURE PERSPECTIVES
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Summary
Renal cell carcinoma (RCC) is the most prevalent malignancy of the kidney. Due to improved
radiological evaluation over 50% of the renal cancers are found incidentally. Despite the fact
that these incidentalomas are often confined to the kidney, around 50% of all patients diagno-
sed with kidney cancer will develop metastatic disease. Metastatic RCC has a poor prognosis.
Traditional treatment modalities like chemo- and radiotherapy show overall response percen-
tages of 2-6%. In view of the observed spontaneous remissions of advanced renal cancer,
immune mechanisms have been suggested to play a role in the natural disease course of RCC.
At present, several non-specific cytokine regimens are used in the treatment of metastatic
RCC, e.g. interleukin-2 and interferon-alpha, in combination or as monotherapy or in combi-
nation with substances like 13-cis-retinoic acid and/or 5-fluorouracil. Collective data of trials
evaluating cytokine-based therapies for metastatic RCC show an overall response rate of
approximately 15%, with 5% of the patients showing complete responses. More importantly,
cytokine treatment clearly translates into a significant survival benefit in a subset of patients.
Nevertheless, the toxicity profile of these cytokine regimens is significant. Therefore, the iden-
tification of prognostic factors and biomarkers is of the greatest importance. They may show
additional prognostic value over classical prognostic factors like stage and grade. Also, these
markers can be used for a better patient selection, development of specific gene-immunothe-
rapy strategies and a better follow-up. In chapter 1 current and future biomarkers of interest in
the diagnosis, treatment and follow-up of patients with RCC are reviewed. Furthermore, the
different immunotherapeutical modalities currently used are discussed in detail.
Outcome prediction for patients with RCC is based on a combination of factors. In chapter 2
a previously published clinical outcome algorithm based on the 1997 T stage, Fuhrman grade
and performance score which stratifies patients into low, intermediate and high risk groups is
validated using an international database. A retrospective analysis was performed on 1,060
patients from Nijmegen, the Netherlands; MD Anderson, Houston, USA and the University of
California, Los Angeles, USA (UCLA). Patients had localized RCC and were evaluated for
outcome prediction using this algorithm. Validation was performed by comparing the 3 risk
groups separately within the 3 institutes as well as by comparing hazard ratios and concordan-
ce indices among the 3 centers. The estimated disease specific survival rates at 5 years for the
low risk groups were 94% (Nijmegen), 92% (MD Anderson) and 93% (UCLA). The 5-year
disease specific survival rates for the intermediate risk groups were 65% (Nijmegen), 73%
(MD Anderson) and 78% (UCLA), while the rates for the high-risk groups were 40%
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(Nijmegen), 30% (MD Anderson) and 48% (UCLA). The concordance indices for each of the
databases were 79% (Nijmegen), 86% (MD Anderson) and 84% (UCLA). In conclusion, a cli-
nical algorithm that uses only 3 prognostic variables (1997 T stage, Fuhrman grade and per-
formance status) to stratify patients with localized renal cell carcinoma into 3 risk groups has
been shown to be applicable to external databases. This algorithm may be useful for patient
counselling, surveillance and identification of high-risk patients for enrolment in clinical tri-
als.
In chapters 3 and 4 the role of dendritic cells (DC) in the development of specific immunothe-
rapy for RCC is discussed. DC have been identified as the most potent antigen presenting cells
of the immune system and collective results of DC-based clinical trials show the safety and
feasibility of this approach.
In chapter 3, a clinical trial is discussed in which twelve patients with metastatic RCC recei-
ved a vaccine consisting of autologous immature DC loaded with autologous tumor lysate. The
treatment was combined with low-dose interleukin-2, as this has shown benefit in DC-based
therapies. Patients received three intradermal vaccinations at two weekly intervals, and, after
each vaccination, interleukin-2 was administered for 5 consecutive days. In six patients,
Keyhole Limpet Hemocyanine (KLH) was added to the DC culture. KLH is a potent immuno-
genic neo-antigen that principally stimulates proliferation of T-helper cells. Furthermore, KLH
can be used as an immunological control. The vaccine was able to elicit cellular anti-KLH res-
ponses, emphasizing the ability of the injected DC to mount an immunologic response.
However, proliferative responses against tumor lysate were not detected, and humoral respon-
ses against tumor lysate or KLH were absent. Objective clinical responses were not observed,
but extended stable disease was noted. The absence of cellular, humoral, or clinical antitumor
responses suggests that the vaccination strategy with immature DC has little benefit for
patients with advanced RCC. Nevertheless, this study shows the feasibility of a completely
autologous DC and tissue culture methodology for the generation of tumor lysate pulsed DC.
In chapter 4, a phase-I clinical trial is described involving CA9-peptide loaded dendritic cells
in patients with progressive, cytokine-refractory metastatic renal cell carcinoma. Carbonic
Anhydrase-IXG250/MN (CA9) is a renal cell carcinoma (RCC)-associated antigen ubiquitous-
ly expressed in the clear-cell subtype of RCC and two CA9-derived peptides have been iden-
tified defining a CTL epitope and HLA-DR epitope respectively able to induce T cell respon-
ses in vitro. Primary objectives were assessment of the safety, toxicity and induction of CA9-
specific immunity.
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Six patients with objective progressive metastatic RCC received 5 vaccinations of mature den-
dritic cells (mDC) pulsed with the CA9-derived peptides and KLH. Peripheral blood was col-
lected at regular intervals, delayed-type hypersensitivity (DTH) was tested at baseline and after
the last vaccination and skin biopsies of positive DTH-sites were collected for immunomoni-
toring purposes. Patients were also monitored for clinical responses. No significant toxicity
was observed. In all patients humoral responses were observed against KLH, as well as DTH
conversion. Evaluation of biopsy material suggested increased influx of T-helper cells. In none
of the immunomonitoring assays evidence for the induction of CA9-peptide specific immuni-
ty was observed. No clinical responses were observed. The lack of induction of CA9-peptide
specific immune responses indicates that this particular peptide combination cannot induce
peptide-specific immune responses.
The concept of selective tumor targeting with antibodies is based on the avid interaction bet-
ween the antibody and an antigen that is expressed on malignant cells, but not on normal tis-
sues. This specificity can be employed to guide toxic substances or radionuclides to the tumor,
but unconjugated antibodies are also able to induce cell death through a variety of mechanisms
such as antibody dependent cellular cytotoxicity (ADCC).
In RCC, the antibody WX-G250 has been identified and developed for both diagnostic and
therapeutic purposes. It recognizes the CA9 antigen that is expressed in >95% of the clear cell
RCC. ADCC is suggested as the main effector mechanism of the ungonjugated WX-250 to
induce cell lysis of RCC. Furthermore, in-vitro studies have shown that several cytokines, e.g.
interleukin-2 and tumor necrosis factor-alpha, are able two upregulate WX-G250-mediated
ADCC. Consequently, two clinical trials were initiated. The results are presented in chapters 5
and 6.
The first trial, discussed in chapter 5, evaluated the toxicity profile, immunogenicity and effec-
tivity of WX-G250 monotherapy. WX-G250 was given weekly by intravenous infusion for 12
weeks. Patients showing stable disease or a clinical response after first treatment cycle were
eligible to receive additional treatment for 8 weeks. The weekly schedule of WX-G250 was
well tolerated. In all, 10 patients had stable disease and received extended treatment. In one
patient a complete response was observed and in another patient significant tumor regression
was observed during the follow-up of the treatment. Five patients with progressive disease at
study entry were stable for more than 6 months after study entry. With a median survival of 15
months after the start of this treatment and two late clinical responses, WX-G250 seems to be
able to modulate metastatic RCC.
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Because the number of activated ADCC-effector cells can be increased by low-dose interleu-
kin-2, a multicenter study, discussed in chapter 6, was initiated to investigate whether WX-
G250 combined with low-dose interleukin-2 can lead to improved clinical outcome of patients
with progressive metastatic RCC. Thirty-five progressive RCC patients received weekly infu-
sions of WX-G250 for 11 weeks combined with a daily low-dose interleukin-2 regimen.
Patients were monitored longitudinally for ADCC capacity. Radiological assessment of the
metastatic lesions was performed at week 16 and regularly until disease progression. A dura-
ble clinical benefit was achieved in 8 of 35 patients (23%; 3x partial response, 5x stabilization
>24 weeks). In general the treatment was well tolerated with little toxicity. In conclusion, com-
bination therapy of the chimeric monoclonal antibody WX-G250 and low-dose IL-2 pulsing
appears to result in a clinically significant benefit for progressive metastatic RCC patients.
Together with a median survival of 22 months the combination of WX-G250 and low dose IL-
2 is superior to WX-G250 monotherapy and seems comparable with current non-specific cyto-
kine regimens for patients with advanced RCC.
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Future perspectives
As discussed in this thesis, a clinical algorithm using 3 well-known prognostic factors (1997
T stage, Fuhrman grade and performance status) can be used to stratify patients that undergo
nephrectomy for localized disease into 3 risk groups. This is useful for patient counselling and
useful to choose the optimal post-operative management for the individual patient. The results
indicate that watchful waiting is adequate treatment for patients in the low risk group only,
while patients in the intermediate risk group, but surely patients in the high risk might benefit
from adjuvant treatment. Unfortunately, little is known about adequate adjuvant therapy for
patients with a high risk for recurrent disease. Given the results with WX-G250 in metastatic
RCC, it will be of interest to evaluate the effect of WX-G250 treatment in an adjuvant setting.
The ideal staging system would stratify patients into 2 risk groups with a 0 and 100% proba-
bility of recurrent disease respectively. Unfortunately, with the current clinical and pathologi-
cal parameters this is not possible. Particularly, the majority of patients fall in the intermedia-
te risk group. Hopefully, the increasing knowledge of molecular markers and gene profiling
will increase the power to discriminate between RCC risk groups, as has been shown for e.g.
breast carcinoma patients. Several markers discussed in chapter 1, e.g. CA9, are suggested to
give independent prognostic information, however, more research is needed to obtain new
(better) antigens and markers in RCC. Expression array analyses have shown promise, but
large cohorts need to be studied before prognostic gene expression signatures become availa-
ble.
The two clinical trials that are discussed in chapters 3 and 4 clearly show the difficulties of cur-
rent dendritic cell-based cancer vaccine research. The feasibility and safety of the approach is
clear but the efficacy is unsatisfactory and to what extend immune responses are directed spe-
cifically against the tumor remains unknown. It is frustrating that dendritic cells, regardless the
phenotype, are able to induce tumor-specific immune responses in-vitro and in animal studies
but fail to do so in the majority of vaccinated patients. Of course, most tumor-associated anti-
gens used in cancer vaccines (including CA9) are essentially self-antigens, with patients being
in a tolorogenic state. This might explain why the CA9-derived peptides used in our study did
not show induction of CTL or humoral responses, despite in-vitro results that show activation
of both CD4+ and CD8+ T-cells directed against the peptides. Nevertheless, parallel studies in
melanoma have been successful, at least in the demonstration of induction of peptide-specific
CTL. The more intriguing are the results of another CA9 peptide vaccination trial with HLA-
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A24 restricted peptides, in which CA9 specific, and more importantly, clinical responses were
observed. Noteworthy is that the responses were observed after numerous vaccines (>11
biweekly vaccinations). Perhaps those peptides are simply more immunogenic. Alternatively,
the extended vaccination might imply that long-lasting immunotherapy is needed to break
local tolerance and/or the immunosuppressive state.
This is consistent with recent insight in tumor immunology revealing that local immunosup-
pression might be one of the major obstacles in the development of an effective immunothe-
rapy strategy. On top of immunosuppression, tumor escape through e.g. downregulation of
HLA molecules or Fas regulation may alter the outcome of immunotherapy. Thus, counterba-
lancing immunosuppression with at the same time potent vaccine strategies might eventually
lead to effective immunotherapies. Indeed, vaccination combined with measures to deplete
regulatory T cells (ONTAK) or blocking T cell downregulation by blocking CTLA-4 has
shown robust anti-tumor responses. However, CTLA4 is important in maintaining immune
homeostasis, and anti-CTLA4 treatment does provoke autoimmune toxicity. Thus far, ONTAK
treatment has not resulted in autoimmune toxicity. Thus a delicate balance between tumor
immunity and autoimmunity exists. A key issue of future research is to determine whether
tumor destruction and severe autoimmunity can be dissociated, e.g. through manipulation of
(antigen) specific Treg populations.
The two clinical studies presented in chapters 5 and 6 indicate that the monoclonal antibody
WX-G250 might play a role in the treatment of RCC. The clinical results seem at least com-
parable with the high-dose non-specific cytokine regimens but with a very favourable toxicity
profile. Consequently, phase-III trials are needed to compare the efficacy of WX-G250 with
the efficacy of the current non-specific cytokine treatments for patients with metastatic RCC.
As mentioned, WX-G250 may be useful in adjuvant treatment for patients macroscopically
free of RCC after nephrectomy with intermediate/high risk for recurrent disease. The clinical
studies failed to confirm ADCC as WX-G250 effector mechanism, although in vitro studies
clearly demonstrated the reverse. Therefore, fundamental research remains essential to gather
more insight into the working mechanism of WX-G250.
So far, the development of specific immunotherapy for cancer has focussed either on the
induction of cellular immune responses through the use of vaccines or passive immunothera-
py by infusion of monoclonal antibodies. However, combining these strategies may induce a
more powerful anti-tumor effect. DC pulsed with tumor cells coated with monoclonal antibo-
dies seem to be able to present the tumor antigens with superior efficiency DC loaded with
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irradiated tumor cells or tumor specific peptides alone. Given the high presence of the CA9
antigen on RCC cells, the WX-G250 antibody will be ideal to explore this strategy in the RCC
setting.
As discussed in chapter 1, mutations in the VHL gene are found in over 75 % of clear cell
RCC. Many of the gene products that are upregulated as a consequence of these mutations are
involved in angiogenesis and proliferation. Subsequently, new therapies are being explored to
block these growth factors. These new treatment modalities include anti-VEGF monoclonal
antibodies (bevacizumab), tyrosine kinase inhibitors (SU-11248), targeting of the Raf kinase
pathway (BAY 43-9006) and inhibition of the mTOR pathway (CCI-779). Based on the first
promising results, further exploration of these compounds has to establish their place in the tre-
atment of RCC. In particular, it will be interesting to combine various treatments: e.g. VEGF-
induced immunosuppression can be inhibited by bevacizumab, which might be beneficial in
vaccination strategies. Secondly, the extend of clinical cross-resistance is unknown, which pro-
vides a rational for combination. Extensive, complicated clinical trials are currently being des-
igned to compare various combination strategies, all aimed at defining a safe and effective 
treatment for metastatic RCC patients. 
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Hoofdstuk 1
Het niercelcarcinoom is de meest voorkomende kanker van de nier, waarvan de incidentie aan
het toenemen is. Door verbeterde radiologische technieken wordt tegenwoordig tot meer dan
50% van alle niercelcarcinomen bij toeval ontdekt. Ondanks het gegeven dat deze zogenoem-
de incidentaloma's zich over het algemeen binnen de nier begeven, ontwikkelt de helft van alle
patiënten gediagnosticeerd met niercelcarcinoom systemische ziekte. Uitgezaaid niercelcarci-
noom heeft een zeer slechte prognose. Traditionele behandelingen zoals chemo- en/of
radiotherapie laten een respons percentage zien van 2-6%.
Aangezien spontane remissies van uitgezaaid niercelcarcinoom in de literatuur worden
beschreven, wordt aangenomen dat het afweersysteem een rol speelt in het ziektebeloop van
niercelcarcinoom. Dit heeft geleid tot de ontwikkeling van non-specifieke immunotherapie en
tegenwoordig kan de behandeling van uitgezaaid niercelcarcinoom door middel van een op
cytokinen gebaseerde therapie als standaard beschouwd worden. Deze therapieën bestaan uit
de cytokinen interleukine-2, interferon-alfa, een combinatie van deze twee of zelfs nog uitge-
breid met 5-fluorouracil. Wanneer men de uitkomsten van verscheidene studies naar deze cyto-
kinen in de behandeling van het uitgezaaide niercelcarcinoom met elkaar vergelijkt, blijkt dat
bij ongeveer 15% van de patiënten een respons te zien is, en bij 5% zelfs een complete remis-
sie van de ziekte. Belangrijker nog, behandeling met cytokinen leidt tot een winst in de over-
leving. Desalniettemin is het bijwerkingen-profiel van deze non-specifieke cytokinen-thera-
pieën significant. Vandaar dat de zoektocht naar prognostische factoren en niercelcarcinoom-
specifieke eiwitten zo van belang is. Deze kunnen een toegevoegde waarde hebben in een meer
adequate patiëntenselectie voor eventuele verdere behandeling. Daarbij kunnen deze eiwitten
de basis zijn voor de ontwikkeling van meer specifieke immuno-gen therapieën. In hoofdstuk
1 wordt een introductie gegeven van het niercelcarcinoom, het immuun systeem en worden de
verschillende immunotherapieën die op dit moment in gebruik zijn bediscussieerd. Tevens
worden verschillende eiwitten beschreven die van belang (kunnen) zijn in  diagnostiek, behan-
deling en follow-up van patiënten met niercelcarcinoom.
Hoofdstuk 2
Met de huidige ontwikkeling van beeldvormende technieken wordt het niercelcarcinoom
steeds eerder ontdekt. Samen met de ontwikkeling van de immunotherapie voor het gevorder-
de niercelcarcinoom heeft dit geleid tot een verbeterde prognose voor niercelcarcinoom.
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Samenvatting
Hierdoor is een vernieuwing nodig van de bestaande prognostische stadiëring classificaties.
Bovendien kunnen in de toekomst op deze wijze subgroepen van patiënten worden geïdentifi-
ceerd die beter zullen reageren op al dan niet specifieke immunotherapie. Vandaar dat het
UCLA de geïntegreerde stadiëring classificatie, UISS heeft ontwikkeld. De UISS heeft de
TNM-classificatie uit 1997 geïntegreerd met de Fuhrman pathologische gradering en de
ECOG performance status. Op deze wijze is het mogelijk op meer individuele wijze patiënten
te karakteriseren.
Het doel van de studie beschreven in hoofdstuk 2 was de validatie van de UISS aan de hand
van een database van patiënten met niet uitgezaaid niercelcarcinoom behandeld in respectie-
velijk het UCLA (Los Angeles), MD-Anderson (Houston) en het UMC St. Radboud te
Nijmegen. In totaal zijn de gegevens van 1.060 patiënten gebruikt voor de validatie. De vali-
datie is uitgevoerd door de patiënten onder te verdelen volgens de UISS om vervolgens de spe-
cifieke overleving van de 3 prognostische groepen te vergelijken tussen en binnen de verschil-
lende centra. De volgende 5-jaars overlevingen werden berekend naar aanleiding van de
onderverdeling: de laag-risico groep 94% (Nijmegen), 92% ( Anderson) en 93% (UCLA); de
gemiddelde-risico groep 65% (Nijmegen), 73% (Anderson) en 78% (UCLA); de hoog-risico
groep 40% Nijmegen, 30% (Anderson) en 48% UCLA.
Deze studie laat zien dat een klinisch algoritme van slechts 3 prognostische factoren in staat is
om patiënten met niet uitgezaaid niercelcarcinoom adequaat onder te verdelen in 3 risico-
groepen. Met behulp van deze risico groepen kan vervolgens een toepasselijke begeleiding en
behandeling worden uitgezocht op de individuele patiënt.
Hoofdstuk 3 & 4
In de behandeling van het uitgezaaide niercelcarcinoom wordt de aandacht steeds meer ver-
legd van non-specifieke immunotherapie, zoals interleukine-2 of interferon-alpha, naar meer
specifieke immuuntherapieën. Hierbij wordt onderandere gebruik gemaakt van dendritische
cel vaccinaties. Dendritische cellen (DC) zijn de meest potente antigeen presenterende cellen
van het menselijk lichaam die in-vitro gekweekt kunnen worden en dus  zeer geschikt zijn voor
de inductie van een tumor specifieke immuunrespons.
In hoofdstuk 3 wordt een studie beschreven waarbij 12 patiënten met uitgezaaid niercelcarci-
noom na de verwijdering van de nier een vaccinatie hebben gehad met DC geladen met tumor-
cellen. De vaccinaties werden gecombineerd met een interleukine-2 behandeling. De drie vac-
cinaties werden om de week in de huid gegeven. Voor, tijdens en na de uitvoering van de stu-
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die is bloed afgenomen voor immunologische monitoring. De uitzaaiingen zijn door middel
van CT-scans geëvalueerd. 
Deze studie laat de veiligheid en haalbaarheid zien van vaccinaties op basis van DC beladen
met tumorcellen. Immunologische monitoring liet een milde reactie zien op KLH, een sterk
immunogeen en lichaamsvreemd controle antigeen. Tumorspecifieke immuunreacties zijn niet
geobserveerd. Geen van de patiënten toonde afname van de uitzaaiingen bij klinische evalua-
tie, al zijn er enkelen langdurig stabiel gebleven en uiteindelijk na operatieve verwijdering van
de uitzaaiingen vrij van meetbare ziekte. Behalve een voorbijgaande temperatuursverhoging
zijn geen bijwerkingen geobserveerd.
Uit diverse studies is gebleken dat er twee populaties DC zijn. Immature DC en mature DC.
In deze studie zijn immature DC gebruikt, vanwege optimale opname van antigenen. Mature
DC zijn daarentegen superieur in de migratie en de presentatie van de antigenen aan T-cellen
en uit verschillende onderzoeken is dan ook gebleken dat het gebruik van mature DC een bete-
re immunologische en klinische respons laat zien.
"Carbonic anhydrase-IXMN/G250" (CA9) is een antigeen wat sterk geassocieerd is met het
niercelcarcinoom aangezien het in meer dan 95% van het clear-cell subtypen van de niercel-
carcinomen tot expressie komt. Onlangs zijn twee peptiden geidentificeerd afkomstig van het
CA9 antigeen die herkend worden door cytotoxische T-cellen (type-I peptide) en T-helper cel-
len (type-II peptide). Dit heeft geleid tot de initatie van de studie zoals beschreven in hoofd-
stuk 4. In dit klinisch onderzoek hebben zes patiënten met progressief uitgezaaid niercelcarci-
noom vaccinaties gekregen van mature DC beladen met de CA9-afgeleide peptdiden. Van deze
patiënten is het bloed geevalueerd voor immunologische responsen, uiteraard is ook gekeken
naar het klinisch beloop.
Zoals bekend uit onze vorige ervaringen met DC-vacinaties en de literatuur zijn geen noe-
menswaardige bijwerkingen gezien tijdens de studie. Immunologische monitoring liet duide-
lijk een sterkere reactie zien tegen KLH in vergelijking tot  de vaccinaties met immature DC.
De DTH-huidtest ("delayed type hypersensitivity") werd bij alle patiënten positief gedurende
de studie voor de DC beladen met zowel KLH als het type-I peptide. Bij de evaluatie van de
huidbiopten van deze positieve huidtesten zijn met name T-cellen en cytokinen geobjectiveerd
die betrokken zijn bij het T-helper "pathway", wat impliceert dat de immunologische reacties
gericht zijn tegen KLH.
Bij geen van de patiënten heeft de behandeling geresulteerd in een klinisch effect.
Kortom, de gebruikte vaccinaties zijn in staat om het immuunsysteem te activeren, maar zon-
der dat er een specifieke afweerreactie tegen de gebruikte peptiden is waargenomen. Blijkbaar
zijn de peptiden gebruikt is deze studie niet in staat om afweerreacties op te wekken. In de te
volgen studies zullen dan ook of het hele antigeen, met alle epitopen, of zelfs hele tumorcel-
len gebruikt gaan worden om te beladen op de mature DC.
Hoofdstuk 5 & 6
Het gebruik van antilichamen binnen de therapie van kanker is gebaseerd op de sterke binding
van het antilichaam met een antigeen wat aanwezig is op de tumor cellen, maar niet op nor-
maal weefsel, een zo genoemd tumor-associated antigen. Deze specificiteit kan gebruikt wor-
den om antilichamen gebonden aan toxische of radioactieve agentia specifiek te sturen naar de
tumor dus alleen daar celdood te induceren.
Ook het ongebonden antilichaam kan echter celdood induceren, onder andere door middel van
het antibody dependent cellular cytotoxicity, oftewel ADCC. ADCC is gebaseerd op de speci-
fieke binding van een antilichaam met een antigeen. Vervolgens herkennen natural killer cells,
NK-cellen, dit antilichaam tumor complex wat leidt tot lyse van de cel.
Voor het niercelcarcinoom is het CA9 eiwit geïdentificeerd. Dit antigeen is aanwezig in meer
dan 85% van alle niercelcarcinomen en in >95% niercelcarcinomen van het clearcell subtype.
CA9 komt niet tot expressie in normaal nierweefsel.
Het antilichaam G250 bindt aan het CA9 antigeen en is ontwikkeld zowel voor diagnostische
als voor therapeutische doeleinden. Het G250 gebonden aan radioactief jodium heeft duidelijk
laten zien dat het specifiek target naar de metastases van de niercelcarcinoom. Voor het onge-
bonden G250 wordt ADCC gezien als belangrijkste mechanisme om celdoor te induceren.
Verder is uit in-vitro onderzoek gebleken dat diverse cytokinen, waaronder interleukine-2, in
staat zijn G250 gemedieerde ADCC op te reguleren.
Deze ontwikkelingen hebben geleid tot de initiatie van twee klinische studies met G250 voor
patiënten met een gevorderd stadium van niercelcarcinoom. Deze beide studies staan beschre-
ven in de hoofdstukken 5 en 6. De eerste studie onderzocht G250 als monotherapie, vervol-
gens is een studie uitgevoerd die de combinatie onderzocht van G250 met een lage dosis inter-
leukine-2. Doelen van beide studies waren de evaluatie van eventuele bijwerkingen van G250
met of zonder IL-2, en de effectiviteit in de vorm van meetbare ADCC in het perifere bloed en
klinische responsen. Patiënten in de combinatie-studie kregen eerst een week IL-2, om IL-2
specifieke bijwerkingen te kunnen monitoren. Vervolgens kregen patiënten een wekelijks
infuus van 20mg G250 gecombineerd met dagelijks een lage dosis IL-2 door middel van zelf-
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injectie. Om de week werd dit IL-2 schema afgewisseld met drie dagen een hogere dosering
IL-2.
In totaal hebben 71 patiënten minstens 1x een infuus gehad met het antilichaam G250. 35 pati-
ënten hiervan in combinatie met een dagelijkse subcutane injectie van interleukine-2. Beide
studies laten een zeer gunstig bijwerkingen profiel zien. De meeste bijwerkingen die door de
patiënten genoemd zijn, waren milde en voorbijgaande klachten van rillingen, koorts en moe-
heid. Deze klachten zijn bekend van interleukine-2 gebruik. De dagboeken die de patiënten
bijgehouden hebben laten zien dat er duidelijk meer klachten genoteerd zijn tijdens en vlak na
de drie dagen hogere dosis IL-2.
Follow-up van de patiënten liet 1 complete response, 4 partiële responders en 11 patiënten zien
met stabilisatie van de ziekte van langer dan 24 weken. In het geval van gemetastaseerd nier-
celcarcinoom wordt dit gezien als een "clinical benefit". Tevens is er een mediale overleving
van rond de 17 maanden. Van de combinatie studie is deze zelfs 22 maanden.
Evaluatie van de ADCC-assays die uit het perifere bloed van deze patiënten gedaan zijn laat
zien dat de interleukine-2 behandeling een duidelijk effect heeft op de hoeveelheid effector
cellen, dus de NK-cellen, in het perifere bloed. De non-specifieke cytotoxiciteit door middel
van NK-cellen gedurende de studie is dan ook significant is toegenomen. Specifieke G250-
gemedieerde cytotoxiciteit wordt echter helaas niet gezien.
Samenvattend laten deze twee studies ons zien dat G250 geen noemenswaardige bijwerkingen
laat zien, en dat de lage dosis interleukine-2 goed te verdragen is. Ondanks het feit dat ver-
schillende in-vitro studies laten zien dat ADCC in staat is niercelcarcinoomcellen te doden,
wordt in deze studies geen significante G250-gemedieerde ADCC gezien. Of de rol van ADCC
in de in-vivo situatie minder van belang is dan gedacht of dat dit het gevolg is van een lokale
immunosuppressie door de tumor cellen moet het onderwerp worden van verdere studies.
Desalniettemin wordt bij 22.5% van de patiënten een klinisch voordeel gezien door deze
behandeling. Verder is de mediane overleving van 22 maanden die gezien is bij de combinatie
studie op zijn minst vergelijkbaar met de op dit moment gebruikte non-specifieke immunothe-
rapieen zoals interferon-alpha en interleukine-2, maar dan zonder de zware bijwerkingen.
G250 lijkt dus in staat het beloop van gemetastaseerd niercelcarcinoom positief te beïnvloe-
den.
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DANKWOORD
Geachte prof. dr. F.M.J. Debruyne,
Het streven om continu op het hoogste niveau te opereren, zowel klinisch als wetenschappe-
lijk, leidt tot een klimaat waarin iedereen gestimuleerd wordt het maximale te geven en te
bereiken. Bedankt voor het scheppen van deze werkomgeving.
Geachte dr. P.F.A. Mulders, Beste Peter,
Om een co-promotor te hebben die als clinicus zo enthousiast bezig is met de integratie van
fundamenteel onderzoek en de (academische) kliniek van alle dag werkt zeer inspirerend. Ik
kijk dan ook uit naar het vervolg van onze samenwerking in het verdere traject van mijn oplei-
ding tot uroloog waarbij de kliniek op de voorgrond zal staan.
Geachte dr. E. Oosterwijk, Beste Egbert,
Dankzij de vele brainstormsessies om onze gegevens zo goed mogelijk op papier te zetten is
de immunologie verworden van een abstract begrip tot…nou ja, een iets minder abstract
begrip. De talloze momenten tussendoor waarin met indrukwekkende geestdrift het werkings-
mechanisme van een fagocyterende interleukine secreterende cytotoxische cel werd uitgelegd,
compenseert volledig al die manuscripten die rood gekladderd terug in mijn u-tje terecht kwa-
men.
Beste Dorien en Jeannette,
De lijn tussen promovendus en analist is bij de Experimentele Urologie flinterdun. Samen zijn
we bezig geweest met het uitdenken van experimenten en de interpretatie van de verkregen
data. Dit gold echter ook de uitvoering van de experimenten. Zeker voor mij als clinicus is dat
erg belangrijk geweest door het inzicht die het daadwerkelijk uitvoeren van de experimenten
verschaft in de data. Ik kan de lezers echter verzekeren dat ik daar bij het uitvullen van well
nummer 649 met 7.5 microliter van het een of het ander daar ook wel eens andere gedachten
over heb gehad. Daar staat tegenover dat de gezelligheid op de kweek of het inzetten van de
DC-kweek van de patiënten op de clean-room tot 's avonds laat onvergetelijke herinneringen
opgeleverd heeft.
Beste prof. dr. J.A. Schalken, Beste Jack & alle medewerkers van experimentele urologie.
Wat hierboven al genoemd is, is uiteraard te extrapoleren naar het hele lab experimentele uro-
logie onder de bezielende leiding van prof. dr. Jack Schalken. De combinatie van levendige
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discussies tijdens de WIP- & literatuur besprekingen, en de evenzo levendige gesprekken tij-
dens de pauze en weekevaluaties bij St Anneke, maken dat de drie jaar op het lab op zeer pro-
ductieve & ontspannen wijze voorbij zijn gevlogen.
Polikliniek Urologie UMC St Radboud,
De beschreven klinische trials in dit boekje staan of vallen mede met goede opvang van pati-
ënten, begeleiding en uitleg over de studies. Op de polikliniek bleek dit een vanzelfsprekend-
heid. Vooral de goede en plezierige samenwerking met Anita, José en Suzanne mag dan ook
hier niet ontbreken.
Collega's in Apeldoorn:
Na 3 jaar wetenschap was het wel even omschakelen naar de chirurgische kliniek. Gelukkig
waren daar de assistenten chirurgie te Apeldoorn: Hard werken, veel lol en vooral soepel rui-
len als er tijd nodig was om artikelen in te dienen.
Alle vrienden, vriendinnen, familie en kennissen.
Namen noemen lijkt me niet nodig, iedereen bedankt.
Lieve Fred, Berna, Anoek, Richard, Joeri, Desiree,
Misschien dat jullie na het lezen van de Nederlandse samenvatting enigszins snappen wat ik
überhaupt gedaan heb… Desondanks bleven jullie oprecht geïnteresseerd in het verloop van
het project en wanneer het feest nou een eindelijk zou volgen.
Lieve Leonie,
Als ik dit dankwoord teruglees, lijkt het wel alsof een promotie project een brok gezelligheid
is. Jij weet wel beter! Al die keren dat er weer een cruciale DC-kweek de mist in ging, een
manuscript niet geaccepteerd werd, en alle andere denkbare teleurstellingen horend bij een
promotieproject, stond jij daar in avonduren en weekeinden klaar om het gezeur te nuanceren,
relativeren en zelfs gewoon aan te horen. Maar ook was je daar om me van de bank af te schop-
pen om door te gaan als het nodig was. 
Baie danki, Dushi!
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Ivar Bleumer werd geboren op 26 december te Tilburg, maar verhuisde binnen enkele maan-
den al naar Nijmegen. Na een tropische tussenstop te Curaçao alwaar de eerste drie jaar van
het atheneum werden gevolgd aan het Peter Stuyvesant College, vervolgde Ivar zijn opleiding
aan het Canisius College Mater Dei te Nijmegen.
In 1993 werd gestart met de opleiding geneeskunde aan de Katholieke Universiteit Nijmegen.
Aansluitend aan het halen van de artsenbul in augustus 2000 startte Ivar met het onderzoeks-
project "Optimalisatie van specifieke immunotherapie voor het niercelcarcinoom" aan de afde-
ling Urologie van het Universitair Medisch Centrum St Radboud te Nijmegen. Het resultaat
daarvan heeft u in handen. In de 2004 startte Ivar met de opleiding tot uroloog aan de afdeling
Heelkunde van Gelre Ziekenhuizen te Apeldoorn (opleider dr. W.H. Bouma) in het kader van
de vooropleiding. Momenteel is Ivar werkzaam aan de afdeling Urologie van het Canisius
Wilhelmina Ziekenhuis (opleider dr. H.F.M. Karthaus). De opleiding zal worden voltooid aan
het Universitair Medisch Centrum St. Radboud te Nijmegen (opleider prof. dr. F.M.J.
Debruyne).
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